

SALMONID ALPHAVIRUS (SAV)

- Genetic characterisation of a new subtype, SAV3,
and implementation of a novel diagnostic method



Kjartan Hodneland

Doctor Scientiarum

University of Bergen, Norway

2006

ISBN 82-308-0282-3

Bergen, Norway 2006

CONTENTS

Acknowledgements.....	5
List of papers.....	7
1 INTRODUCTION.....	9
Background.....	9
The Alphavirus (<i>Togaviridae</i>)	11
General Alphavirus structure.....	11
Replication cycle of Alphaviruses.....	13
Evolution of RNA viruses.....	18
Alphaviruses in fish; SAV.....	20
Molecular characteristics of SAV	22
SAV pathology and diagnostics	27
Fish sera; neutralising Abs against SAV.....	32
Polyclonal antisera and mAbs against SAV.....	33
Epizootiology	37
Potential use of SAV in vaccinology	44
2 AIMS OF THE PRESENT STUDY.....	46
3 OVERVIEW OF PAPERS.....	46
4 GENERAL DISCUSSION.....	49
Genomic sequence diversity within SAV.....	49
Real time PCR as a screening- and diagnostic tool.....	53
SAV; differential diagnostics.....	57
Diseases caused by SAV; - are they different?	62
Conclusions.....	65
5 REFERENCES.....	67

Acknowledgements

This work has been carried out at the Department of Biology, University of Bergen, and received financial support from the Norwegian Research Council.

I would like to thank my supervisors Professor Curt Endresen and Professor Are Nylund at the University of Bergen for their support and guidance. Furthermore, I am thankful to my co-authors and to all of you who have helped me complete this thesis.

List of papers

This thesis is based on the following papers, hereafter referred to in the text by their Roman numerals:

Paper I

Hodneland, K., Bratland, A., Christie, K.E., Endresen, C. and Nylund, A., 2005. New subtype of salmonid alphavirus (SAV), Togaviridae, from Atlantic salmon *Salmo salar* and rainbow trout *Oncorhynchus mykiss* in Norway. Dis Aquat Organ 66, 113-120.

Paper II

Karlsen, M., Hodneland, K., Endresen, C. and Nylund, A., 2006. Genetic stability within the Norwegian subtype of salmonid alphavirus (family Togaviridae). Arch Virol 151, 861-874.

Paper III

Hodneland, K. and Endresen, C., 2006. Sensitive and specific detection of Salmonid alphavirus using real-time PCR (TaqMan®). J Virol Methods 131, 184-192.

1 INTRODUCTION

Background

Since the onset of large-scale commercial salmon farming in Norway in the 1970-ies the industry has more or less continuously been hampered by “new” emerging diseases. As history has shown diseases originally with unknown aetiology, are in fact old pathogens that must have existed in nature long before salmonids were commercially domesticated. For instance ISAV, first reported in 1984 (Thorud, 1991), was initially called Bremnes syndrome and there were speculations on a bacterial aetiology (Hitra disease) or possible malnutrition. Years later, in 1993, final evidence for a viral aetiology was established (Watanabe et al., 1993). Also pancreas disease (PD), the pancreatic disorder first described from Scottish salmon (Munro et al., 1984), had an unknown aetiology for many years until the virus was isolated in by Nelson et al (1995). Although an infectious agent was suspected there was also some discussion on whether PD was a nutritional deficiency disease related to low Vitamin E and/or selenium (Bell et al., 1987; Ferguson et al., 1986b; Munro et al., 1984; Raynard et al., 1991; Rodger, 1991).

In the aquaculture industry at least two contributing factors are responsible for the enzootics observed for many of the diseases in fish; firstly, the naturally occurring pathogen have, through the high stocking densities of hosts occurring in intensive rearing, been given optimal conditions for replication and transmission and thereby have the potential to reach epizootic proportions. Secondly, any unintentional introduction of the pathogen(s) to naïve hosts or areas, by for example transport of infected hosts or otherwise infected material, can have detrimental effects on the newly exposed population of fish. Thus, a crucial measure in the prophylaxis of pathogens is to avoid introducing pathogens to farm sites via transport of new fish stocks that are put into production. One way of achieving this would be to test the fish-

stock for a particular pathogen before importing the fish into the facility. Other general preventive measures to reduce the importance of pathogens in a fish farm include vaccination whenever possible, regulations on transport and distribution of fish, slaughter and quarantine regulations, as well as sound farm management with good hygiene in order to reduce stress and/or physical damage to the fish resulting from unnecessary handling or transport. Today, efficacious vaccines are available for many of the bacterial pathogens in the salmon farming industry. The same success with viral fish vaccines has not been accomplished, and commercially available vaccines against infectious pancreas necrosis virus (IPNV), infectious salmon anaemia virus (ISAV), infectious haematopoietic necrosis virus (IHNV) and salmonid alphavirus (SAV) have considerable limitations in terms of protection and applicability (Sommerset et al., 2005). Especially IPNV and ISAV have been considered important viral pathogens in Norwegian salmon industry, but in recent years SAV has been recognized as a serious pathogen causing a dramatic increase in numbers of pancreas disease outbreaks. In the period from 1995 to 2004 a total of 137 farm sites were diagnosed with pancreas disease compared to 117 ISAV positive farms (E. Brun, National Veterinary Institute, Norway, pers. comm.). Despite that SAV has been known for more than ten years and has emerged as a serious threat to the salmon farming industry, our knowledge on the virus causing pancreas disease in Norway is very limited.

In the next sections some aspects regarding the general alphavirus biology are summarized following a review of the disease-causing alphavirus species in fish; Salmonid alphavirus (SAV), with emphasis on the Norwegian subtype of SAV.

The Alphavirus (*Togaviridae*)

The family *Togaviridae* consists of two genera; *Alphavirus* and *Rubivirus* (Schlesinger and Schlesinger, 2001). Their genomic organization is similar, but phylogenetic analyses have suggested that alphaviruses and rubiviruses are only distantly related (Koonin and Dolja, 1993). Rubella virus is primarily transmitted either through direct contact, inhalation of aerosol containing virus, or congenitally from mother to child. Alphaviruses on the other hand are typically transmitted by arthropod vectors, mainly by mosquitoes of *Aedes* and *Culex* families (Chamberlain, 1980), but also other haematophagous arthropods such as mites, bugs and ticks may function as vectors (Griffin, 2001). This two-host lifecycle gave rise to the historical classification of alphaviruses as arboviruses (arthropod-borne viruses). The alphaviruses use a wide variety of vertebrate hosts and are reported from all continents of the world except Antarctica. The genus *Alphavirus* contains at least 24 different species (Powers et al., 2001), some of which are responsible for important human diseases such as encephalitis ((Eastern (EEE), Venezuelan (VEE) and Western (WEE) equine encephalitis viruses)) or fever, rash and polyarthritis ((Chikungunya, O'Nyong- Nyong (ONN), Ross River and Sindbis (SIN viruses)) (Strauss and Strauss, 1994). Recently, a new species in the *Alphavirus* genus has been described from salmonid fish, for which the name *Salmonid Alphavirus* is proposed (Weston et al., 2002).

General Alphavirus structure

Members of the Alphaviruses are small (45 to 75 nm in diameter), enveloped viruses, and have an icosahedral nucleocapsid core surrounded by a membrane bilayer. The nucleocapsid consists of one copy the positive (+) single-stranded RNA genome complexed with 240 copies of the capsid protein. Individual capsid proteins are arranged as pentamers and

hexamers to form a T=4 icosahedral symmetry (Cheng et al., 1995; Paredes et al., 1993). This symmetry is also maintained for the viral glycoproteins embedded in the lipid bilayer surrounding the nucleocapsid. The lipid bilayer of the virion has a phospholipid composition that resembles that of the host plasma membrane, and anchored in this virion envelope are 80 copies of viral glycoprotein spikes (Figure 1). Each spike on the virus surface is composed of a trimer of two or three subunits; the glycoproteins E1 and E2 (E1/E2)₃, and in some alphavirus species an additional peripheral protein E3 (E1/E2/E3)₃. The latter subunit is normally extremely efficiently cleaved and released from the E2 precursor protein (PE2),




Figure 1. Left: Electron micrograph image of *Salmonid alphavirus* particles (arrows). Middle: Schematic reconstruction of an Sindbis virus indicating the arrangements of the glycoprotein spikes. Right: Cross-section representation of Sindbis virus with the glycoproteins (E1 and E2), the phospholipid bilayer, nucleocapsid, and RNA.

thus rendering the mature virus particle free of E3. E1 and E2 form a stable heterodimer, and three copies of these E1-E2 heterodimers are intertwined to form one spike. The virus contains 240 heterodimers, and these are assembled into 80 spikes organised into the T=4 icosahedral surface lattice (Cheng et al., 1995; Fuller, 1987; Fuller et al., 1995; Vogel et al., 1986).

The carboxy-termini (-COOH) of the E1 and E2 membrane spanning anchors interact with the capsid, while the amino termini of both E1 and E2 face outward from the lipid membrane. In addition, a small hydrophobic viral protein called the 6K is associated with the membrane. Although 6K is expressed from the same open reading frame (ORF) at equal rates as the capsid, E3, E2 and E1, it is associated with the virus in low quantities from 7 to 30 molecules per virus particle (Gaedigk-Nitschko and Schlesinger, 1990; Lusa et al., 1991). The exact role of 6K is not fully understood, but it is believed to be a virally encoded ion channel protein (viroporin) (Melton et al., 2002) that has been shown to affect glycoprotein processing, transport of proteins through the ER, and virus budding (Loewy et al., 1995; Sanz and Carrasco, 2001; Sanz et al., 2003; Yao et al., 1996).

Replication cycle of alphaviruses

Alphaviruses enter the cell by receptor-mediated endocytosis (RME), and are delivered intact into endosomes (Helenius et al., 1980; Kielian et al., 1986) (Figure 2). Since the alphaviruses have a wide host range and are capable of replicating in many different cell types, the interaction with a receptor on the surface of the target cell must involve either many types of protein receptors, and/ or one ubiquitous molecule on the surface of host cells. The highly conserved laminin-receptor found in mammals, birds and mosquitos has been recognized as a high-affinity receptor used by alphaviruses. Other known cell-receptors for alphavirus attachment include two surface-proteins (74-kd and a 110-kd) found on neuroblastoma cells of mouse, and the heparan-sulphate proteoglycan receptor found on most cell types. It appears that the E2 glycoprotein of alphaviruses is responsible for the receptor binding to cells, and that E1 only plays a limited role (Cheng et al., 1995). Studies from Sindbis virus have shown that important neutralizing epitopes reside in a domain between aminoacid residues 170 to 220, and that this domain interacts directly with cellular receptors (Strauss and Strauss, 1994).




Figure 2. Replication cycle of Alphavirus (see main text for details); 1, The virus particles enter the cell via receptor-mediated endocytosis mediated by E2 and become internalized in endosomes. 2, The lowering of the pH in the endosomes triggers the membrane fusion activity of E1, allowing the release of the nucleocapsid into the cytoplasm. 3, The 49S (+) RNA genome binds to ribosomes, resulting in the synthesis of the nonstructural polyprotein (P1234). 4, Autoproteolytic cleavage of P1234 produces the replicase complex P123-nsP4 which transcribes the genome into full-length 42S minus-strand RNA-templates. 5, Only 3-4 hours after infection the cleavage of P123 is accelerated as a result of the accumulation of P123-nsP4 in infected cell, producing four mature proteins nsP1- 4. Then the minus strand production ceases and the newly formed replicase complex nsP1-4 produces only plus-strand RNAs (49S and 26S). 6, The subgenomic 26S RNA is translated into the structural proteins as a polyprotein consisting of capsid-P62-6K-E1. The capsid is autoproteolytically cleaved in the cytosol, and the remaining polyprotein is translocated to the lumen of the ER. 7, After binding to carbohydrate chains the polyprotein is cleaved by signalases into p62, 6K, and E1. The p62 and E1 proteins associate into heterodimers which are transported to the Golgi complex and transferred to the plasma membrane. 8, After assembly of the capsid and viral genomic RNA the nucleocapsid bind to the glycoproteins at the plasma membrane, initiating the budding process.

Once the virus is bound to its cell surface receptor, it accumulates in coated pits which become endocytosed and internalized in an endosome (cf. Strauss and Strauss, 1994). The viral envelope then fuses with the endosome membrane, and the nucleocapsid (NC) is released into the cytoplasm. This fusion process is hypothesised to be pH-dependent, and to require the presence of cholesterol on the target membrane. The lumen of early endosomes become mildly acidic, and it has been shown that this low pH triggers conformational changes in the viral spike proteins. More specifically the E2/E1 heterodimer dissociates when the pH is lowered (Wahlberg and Garoff, 1992) and E2 moves away. As a result, the position of the E1 is altered somewhat so that it facilitates the interaction with cell surface components via its fusion domain. The putative fusion domain in E1 is believed to reside in a highly conserved, hydrophobic region between residues 78 and 98 (cf Strauss and Strauss, 1994). Following the dissociation of the E2/E1 heterodimer the E1 becomes trimerized, and it is postulated that groups of five copies of the homotrimerized E1 will force the two opposed membranes (virus envelope and endosome membrane) together (Gibbons et al., 2003; Gibbons et al., 2004).

After fusion of the two membranes the nucleocapsid enters the cells cytoplasm and dissociation of the nucleocapsid starts almost immediately. It is proposed that the trimerization process of the E1 subunits leads to pore formation in the membrane of the mildly acidic endosomes, and that the influx of protons through the pores forces the capsid protein to undergo a structural change. The conformational change primes the nucleocapsid for final disassembly by interactions with the capsid ribosome-binding site and the ribosomes (Lanzrein et al., 1994; Mrkic et al., 1997).

Once released into the cytoplasm the alphavirus genome binds to ribosomes and serves directly as the messenger RNA for protein synthesis, and as a template for the synthesis of the complementary 42S minus strand (Figure 3).




Figure 3. A schematic alphavirus genome organization. (See text for details). The 5' two thirds of the genome codes for the nonstructural proteins nsP1-4, which are directly translated and processed from the plus-strand genome. The complementary minus-strand of the viral genomic RNA (vcRNA) is synthesized by a P123-nsP4 replicase complex, and serves as a template for the transcription into a 26S subgenomic mRNA. vcRNA is also a template for the generation of new plus-strand genomic RNA by the action of a nsP1-4 replicase complex. Translation of the 26S mRNA results in a polypeptide consisting of capsid-p62-6K-E1. Enzymatic processing of the polypeptide produces the structural proteins capsid, E3, E2, 6K and E1.

The read-through of the 5' two thirds of the 42S alphavirus genome is translated into a single polyprotein P1234 which is autoproteolytically cleaved, by function of nsP2, into a replicase

complex consisting of P123 and nsP4. These proteins form an RNA-dependent RNA polymerase complex that transcribes the genome into full-length 42S minus-strand RNA-templates. Three to four hours after infection, the build-up of proteinases in the cell renders this replicase complex unstable, and the P123 is further cleaved into nsP1, nsP2 and nsP3. The resulting nsP1-4 now constitutes a highly efficient replicase complex that only produces (+) strand RNAs (cf Strauss and Strauss, 1994).

A full-length 42S minus strand serves as template for the synthesis of the subgenomic 26S mRNA, which corresponds to the last one third of the genome. The 26S RNA encodes the viral structural proteins; capsid, E1 through E3 and 6K. This structural domain is transcribed as a polyprotein consisting of capsid-P62-6K-E1. The capsid protein is autoproteolytically cleaved from the polyprotein, and rapidly associates with genomic 42S RNA in the cytoplasm to form icosahedral nucleocapsid structures (cf Garoff et al., 2004; Strauss and Strauss, 1994). A signal sequence on the remaining p62-6K-E1 results in the translocation of the polypeptide to the lumen of the rough endoplasmic reticulum (Garoff et al., 1990; Garoff et al., 1978). Here, the polypeptide is modified by covalent attachment of oligosaccharides, and later proteolytically cleaved into p62, 6K, and E1 (Liljestrom and Garoff, 1991). The p62 and the E1 proteins interact to form heterodimeric complexes in the ER, and are then transported to the Golgi complex. After transport through the Golgi complex the glycoproteins are delivered via the secretory pathway and accumulate in the plasma membrane of the host cell. During the transport via the Golgi network, but before the appearance at the plasma membrane, p62 is already oligomerized into E2 and E3 (de Curtis and Simons, 1988). The cytoplasmic nucleocapsids are thought to diffuse freely to the sites of the plasma membrane where the viral glycoproteins are embedded. There the cytoplasmic C-terminus of the E2 in the glycoprotein spike bind in a 1:1 molar ratio to the newly arrived nucleocapsids, and initiates the final assembly and budding of new viruses will occur. Also,

lateral interactions between glycoproteins are essential for an effective budding of virus. It has been proposed that the nucleocapsid-E2 binding triggers the spikes to interact laterally with each other, and that these spike-spike interactions are responsible for the viral envelope formation (Garoff and Cheng, 2001). As the number of bindings between nucleocapsids and glycoproteins increase, the glycoprotein-containing membrane become tightly pulled around the nucleocapsid until the whole particle is surrounded with the membrane and finally buds off (Garoff et al., 1998).

Evolution of RNA viruses

The success of RNA viruses as intracellular parasites is largely due to their simplicity and small size, but most important is their ability to quickly respond and adapt to changing environments. The reason for their adaptive strength is coupled with the high substitution rates, short replication times, and large population size potential. RNA viruses have the highest substitution rates found in nature ranging from 10^{-3} to 10^{-5} misincorporations per nucleotide copied (Drake and Holland, 1999). The high rate of spontaneous substitution is thought to be a result of absence of proofreading activities of RNA replicases and retrotranscriptases (Steinhauer et al., 1992). Together with the short replication times and usually large population sizes, the RNA virus population will consequently consist of a complex collection of genomes with different substitutions rather than as copies of one or a few dominant sequences. The sequence diversity will then consist of the single master RNA genome sequence, plus all the different mutants in the population. This complex dynamic entity is often referred to as a ‘quasispecies’ (Domingo et al., 2001) (Figure 4).



Figure 4. This picture of a globular star cluster can be used as an analogy to exemplify the concept of the quasispecies. If each point in regular 3-dimensional space corresponds to a genome sequence, then the sum of all stars represent the collection of genomes that form a complex RNA population. At the centre of the cluster is the master sequence (arrow). Immediately surrounding it are sequences with 1 error. Sequences with 2, 3, and more errors are progressively farther out. (Modified from: <http://www.microbiology.wustl.edu/dept/fac/huang/ccas/mut/mut.html#m13>)

Despite the fact that RNA viruses may have a quasispecies distribution which constantly generates new mutants, the master genome is maintained at a stable frequency in the population during passaging in in-vitro systems (such as cell-culture). This is because advantageous mutants will continue to replicate faster than deleterious ones as long as the environmental conditions (cell-culture) remain stable (Steinhauer and Holland, 1987). This explanation for the maintenance of the master sequence in culture may also apply to evolution in nature. Only those features that are the most strongly selected for under a variety of environmental conditions will remain conserved. The frequency of any mutant in the quasispecies is determined by its own replication success, as well as the probability that it will arise by the erroneous replication of other mutants in the population. The replication success in turn is governed by selective forces during changing environmental conditions, and the quasispecies is thought to evolve towards an equilibrium of mutation-selection processes which maximize the average rate of replication of the mutant spectra as a whole. As a consequence of this huge collection of genome variants, a mutant of initial lower fitness may

possess a selective advantage over the master sequence when the environmental conditions change, and will thus become the dominant species. Changing environmental conditions may be exposures to different host species or cell types, and various immune responses (inflammatory action, interferons). Although much cited, there are contradicting views on whether the quasispecies concept is a meaningful theory of RNA virus evolution compared to conventional population genetics. However, according to Wilke (2005) there are no real contradictions between the two, and he concludes that the quasispecies theory is perfectly equivalent to the concept of mutation-selection balance developed in population genetics. A mutation- selection balance states that the deleterious genetic variant in an infinite population will reach an equilibrium between the rate at which the mutant gene arises by recurrent mutation, and its elimination by natural selection.

Despite the high substitution rates in RNA viruses the evolutionary rates may vary considerable, ranging from 10^{-2} to $<10^{-6}$ nt substitutions per site per year. Slow rates of evolution seem to be a general feature among arthropod-borne viruses, which has been attributed to stabilizing selection for successful replication in both the vertebrate host and the invertebrate vector (Weaver et al., 1992). There are however arboviruses such as the North and South American EEEV which have a non-uniform evolutionary rate. Possible explanation for the increased rate in some EEEV lineages involve changes in virus dispersal and population sizes due to fluctuations in the vertebrate host and/or invertebrate vector, or other rapid evolutionary changes such as genetic bottlenecks or founder effects. (Weaver, 1995).

Alphaviruses in fish

Today, the only alphavirus species known from fish is the Salmonid alphavirus (SAV), which can be divided into three subtypes; SPDV/SAV1 (Weston et al., 1999), SDV/SAV2 (Villoing et al., 2000a) and NSAV/SAV3 (**Paper I**).

The first concrete evidence for an Alphavirus in fish was presented from Ireland by Weston et al., 1999). Cloning and sequencing of a 5.2 kb fragment of a virus isolate from salmon suffering from PD, demonstrated a gene organization and sequence similarity which agreed with an alphavirus aetiology. This milestone in the SAV research was published 23 years after PD was first recognized in Scotland in 1976 (Munro et al., 1984). Many new records and descriptions of PD were published in the following 10 years from Scotland (Ferguson et al., 1986a; Ferguson et al., 1986b; McVicar, 1987; McVicar, 1990), Ireland (Murphy et al., 1992; Rodger, 1991), North America (Kent and Elston, 1987), and Norway (Poppe et al., 1989). Depending on which clinical signs and histopathological lesions that were most prominent in the examined tissues in these studies, the disease has been given different names such as exocrine pancreas disease (Munro et al., 1984), polymyopathy syndrome (PMS) (Roberts, 1989) or sudden death syndrome (SDS) (Rodger, 1991). These are all thought to describe the disease now commonly referred to as pancreas disease or PD, although the pancreas lesions itself are not always the most significant histopathological finding.

Parallel to this, a disease with similar histopathology was described from freshwater reared rainbow trout in France. The name sleeping disease was given due to the striking behaviour where diseased fish rest on their side on the bottom of the tanks, but when handled start swimming for some time before returning to “sleep” (Boucher and Baudin Laurencin, 1994). The virus responsible for SD was isolated by Castric et al (1997), and the first nucleotide sequence (Villoing et al., 2000a) showed that the SD and SPDV virus were closely related. Historically, PD in Norway was believed to be caused by the same virus as in the British Isles (SAV1), but it is now accepted that the only SAV present in Norway is the newly characterized NSAV/SAV3 (**Paper I; Paper II**). Infections with SAV seem to be restricted to the two genera *Oncorhynchus* and *Salmo* (Table 1).

Table 1. Records of naturally occurring- or experimental infections with SAV from different fish hosts in either fresh- or seawater conditions.

Host	SAV1		SAV2		SAV3	
	Natural	Experimental	Natural	Experimental	Natural	Experimental
<i>Salmo salar</i>	Yes ^b	Yes ^c	Yes ^a	Yes ^a	Yes ^c	Yes ^c
<i>Oncorhynchus mykiss</i>	No	Yes ^a	Yes ^{c*}	Yes ^a	Yes ^b	No
<i>Salmo trutta</i>	Yes ^b	Yes ^a	Yes ^a	Yes ^a	No	No
Other	No	No	Yes [†]	No	No	No

^a from freshwater

^b from seawater

^c from freshwater and seawater (* as "Summer lesion" in seawater reared rainbow trout (Baudin Laurencin et al., 1985))

[†] Coho salmon (Boucher, P. and Baudin Laurencin, F., 1994)

Molecular characteristics of SAV

The first molecular evidence of SAV came with Weston et al's (1999) cloning and sequencing of a 5.2 kb fragment of the virus (SAV1) previously isolated by Nelson et al (1995) in Ireland. The translated nucleotide sequence showed considerable organizational and sequence identity to the structural proteins from other alphaviruses. Later sequencing studies of SAV1, SAV2 and SAV3 confirmed the phylogenetic position of SAV as an alphavirus species (**Paper I**; Villoing et al., 2000a; Weston et al., 2002).

The nucleotide sequence identity of the three SAVs is above 90 % over the complete genome, while the similarity to the mammalian Alphaviruses is much lower (**Paper I**). As for all Alphavirus two open reading frames (ORF's) are also present in the SAV genome; first a continuous ORF encoding the four nonstructural proteins (nsP1-4) and a second ORF encoding the structural proteins (Capsid, E1-3 and 6K) (Table 2).

Table 2. Comparison of protein sizes (aa) for nonstructural and structural proteins in SAV.

Virus protein	SAV1	SAV2	SAV3
nsP1	562	561	561
nsP2	859	859	859
nsP3	571	564	558
nsP4	609	609	609
C	282	283	281
E3	71	71	71
E2	438	438	438
6K	68	68	68
E1	461	462	461

The first ORF is flanked at its 5' end by a 27 nt long nontranslated region (NTR) and a 35 nt long NTR at the 3' end, which immediately precedes the second ORF (Weston et al., 2002). The second ORF contains approximately 90 nt at its 3' end followed by a poly(A) tract. Full length sequences, excluding the poly(A) tracts at the 3' termini, consist of 11,919 and 11,900 nt for SAV1 and SAV2. The SAV3 sequence lacks approx. 8-53 nucleotides at the 5' end of nsP1 but is otherwise complete at 11,831 nucleotides.

A phylogenetic analysis of 11,700 nt from six different isolates of SAV clearly indicates that the salmonid alphavirus species constitute 3 different subtypes (**Paper I**) (Figure 5). This conclusion was later supported in a phylogenetic study by Weston et al (2005) on nt sequences from E1 and nsP4 gene fragments from SAV isolates originating from British Isles, France and Norway. A comparison of the nucleotide and amino acid sequence identities of the individual nonstructural and structural proteins for all SAVs are summarized in Table 3 and 4. The aa sequence differences between the three subtypes range from 97-98% for the nonstructural proteins, and 94.4-95% for the structural proteins. A pairwise comparison of SAV and selected members of the alphaviruses show that SAV is distantly related to all the established members of the genus *Alphavirus*; the average percentage amino acid identity of

SAV and other alphaviruses is 42.5% for the nonstructural and 32.5% structural proteins (Weston et al., 2002, present study). In general, the SAVs contain larger individual




Figure 5. Salmonid alphaviruses (SAV). Genetic distance of the SAV subtypes in relation to each other. Evolutionary relationship based on alignment of complete genome (11720 nucleotides) of 6 SAV isolates including all 3 subtypes (SAV1, SAV2 and SAV3). Scale bar: number of nucleotide substitutions as a proportion of branch length. Percent nucleotide similarity between the subtypes is shown.

nonstructural and structural proteins compared to other alphaviruses, whereas within SAV there is very little variation. The only exception in this respect is nsP3 which is the most divergent gene with a number of nt substitutions. The mean aa identities are 95-96% for the nonstructural and structural proteins as a whole, but for nsP3 alone the aa identities is 91-93%

for the SAV subtypes (insertions/deletions excluded). In addition, the nucleotide lengths of nsP3 range from 1713, 1692 and 1674 nt in SAV1, SAV2 and SAV3, respectively.

Table 3. Salmonid alphavirus (SAV). Percent nucleotide (nt) sequence similarities between the 3 subtypes in Europe, comparing the different ORFs (open reading frame of SavH10/02 isolate) on the genomic strand.

Subtype	Isolate	SAV3 (SavH10/02)								
		nsP1*	nsP2	nsP3	nsP4	C	E3	E2	6K	E1
SAV3	N3-1997	99	99	99	100	99	99	99	99	100
SAV3	SavH20/03	100	99	99	99	100	100	99	100	100
SAV3	SavSF21/03	99	100	99	100	99	99	99	100	100
SAV1	F93-125	94	91	85	92	91	89	89	94	93
SAV2	S49P	95	93	88	94	88	92	92	94	93
	ORF/nt	1631*	2577	1674	1829	845	210	1316	206	1385

* A few nucleotides are missing at the beginning of the ORF

Table 4. Salmonid alphavirus (SAV). Percent amino acid (aa) sequence similarities between the 3 subtypes in Europe, comparing the different proteins.

Subtype	Isolate	SAV3 (SavH10/02)								
		nsP1*	nsP2	nsP3	nsP4	C	E3	E2	6K	E1
SAV3	N3-1997	100	99	99	100	100	98	99	98	100
SAV3	SavH20/03	100	100	100	100	100	100	100	100	100
SAV3	SavSF21/03	100	100	99	100	100	98	99	100	100
SAV1	F93-125	95	96	88	97	95	94	95	97	98
SAV2	S49P	97	97	90	98	88	95	94	95	96
	No. of aa	543	859	558	609	281	71	438	68	461

* A few aa are missing at the beginning of the protein

The alphavirus genome contains sequence elements and secondary structures that are important for replication of the genomic RNA and its encapsidation, as well as transcription of the subgenomic 26S RNA. The four conserved nucleotide sequence elements, CS 1-4, are believed to be crucial for the replication of alphaviruses, possibly as promoters in the

replication of viral RNA. The putative CS1 is found in the 5' NTR of SAV1 and SAV2, although the sequence similarity with other alphaviruses is low. CS2 is located within the nsP1 and consists of a 52 nucleotide sequence capable of forming two stem-loop RNA structures in all SAVs. It is proposed that the CS2 have an important role in the minus-strand synthesis of alphaviruses. CS3 is part of the junction region between the nonstructural and structural proteins, and act as a transcriptional promotor for the subgenomic mRNA. This 24 nt sequence is identical for SAV2 and SAV3, with SAV1 differing at only 1 nt. A conserved 19 nt region in the 3' nontranslated region has been identified in all SAVs, and is thought to represent the CS4 which serves as a promotor for the initiation of minus-strand RNA synthesis (Villoing et al., 2000a, present study).

For many alphaviruses the translation of the first open reading frame (ORF) stops at an opal termination codon (UGA) between nsP3 and nsP4, thus producing the translation product P123. However, read-through of this stop codon occurs during ~10-20% of the translation events, and will instead result in the incorporation of an additional aa-residue in the new translation product P1234 (Strauss and Strauss, 1994). None of the SAV subtypes have a stop codon in this position, and alignments of the nsP3 and nsP4 region from SAV and other alphaviruses show that this termination codon in SAV is replaced by a glutamine (**Paper I**; Weston et al., 2002). The lack of an opal stop codon is also described in other alphaviruses (SFV and ONNV), but here UGA is replaced by an arginine residue in the polypeptide P1234 (Levinson et al., 1990; Takkinen, 1986).

Several of the conserved aa-motifs in the structural and non-structural alphavirus proteins can also be identified in SAV. For the non-structural proteins these include motif I, II and IV in the nsP1, the -G-X-X-G-X-G-K-T- motif in the nsP2, and the conserved residues Cys482 and His552 within the cysteine protease domain in nsP2 (**Paper I**; Weston et al., 2002). For Sindbis virus, the characteristic catalytic triad amino acid residues H¹⁴², D¹⁶³ and S²¹⁵

constitute the serine protease active site in the nucleocapsid. A corresponding serine protease site is also present in the capsid of SAV, although the position of the H-D-S triad is slightly different (Villoing et al., 2000a). The consensus sequence of the putative autocleavage site in the capsid is also present, and is identical for all SAVs (-P-W[↓]T-). Host mediated cleavage of the p62 into E2 and E3 is proposed to be located within the consensus furin site -R-X^R/K-R[↓]X. The expected size of E2 is observed (approx. 50kDa) in both SAV1 (Welsh et al., 2000) and SAV2 (Villoing et al., 2000a), indicating efficient cleavage of the p62. In SAV2/SAV3 the p62 furin cleavage site is identified as -R-K-K-R[↓]X-, but is slightly different in SAV1 (-R-R-K-R[↓]X-). There are no N-linked glycosylation sites present in the E3 protein in SAV, one site in E2 at N₃₁₉, and one site at position N₃₅ in E1. The SAV E2 protein also contains a putative transmembrane and cytoplasmic tail domain located near the carboxy end. The cytoplasmic tail domain contains two highly conserved cysteine (C₄₃₁ and C₄₃₂) residues. A multiple sequence alignment of E1 identified the putative fusion domain in SAV, and showed high sequence similarities with other alphaviruses (Villoing et al., 2000a). Of particular interest is the replacement of two glycine residues in SAV (G→N₉₄ and G→A₁₀₂), which theoretically would shift the pH threshold for fusion to a more acidic range.

SAV pathology and diagnostics

The disease caused by infections with SAV; pancreas disease (PD), was originally described solely on the basis of exocrine pancreas pathology (Munro et al., 1984), which included vacuolisations and complete necrosis of acinar pancreatic cells with subsequent replacement by fibrotic tissue. The pathogenesis was divided into three phases (preacute, acute and postacute) based on the severity of the degenerative changes. Although the attempts to experimentally infect salmon and rainbow trout failed, they suspected a viral aetiology. It was also speculated that the observed pancreas pathology was a possibly result of selenium

deficiency. It soon became evident that pathologies associated with SAV infections were more extensive and complex than only the exocrine pancreas lesion reported by Munro et al (1984). Ferguson et al (1986) described severe degenerative myopathy in both heart and red skeletal muscle, and concluded that the extensive myocardial lesions were the most significant change associated with SAV diseased fish. Similar degenerative lesions were also observed in the oesophageal muscle and muscle fibres elsewhere in affected fish. However, the only consistent tissue lesion in SAV affected fish was considered by McVicar (1986, 1987) to be necrosis of the exocrine pancreas, and the significant myopathies reported by Ferguson et al (1986) was not always evident in his material. He thus concluded that “*total loss of the exocrine pancreas was the only tissue lesion always found in early stages of the disease and this remains the only reliable pathological index of PD*”. This rigid diagnostic criteria by McVicar (1986; 1987) and/or Munro et al’s (1984) use of exocrine pancreas necrosis as a sole diagnostic criteria for SAV disease was adopted by several authors in the following years (Boucher et al., 1995; Houghton, 1994; Houghton, 1995; Lopez-Doriga et al., 2001; Murphy et al., 1992; Pringle et al., 1992; Raynard and Houghton, 1993; Rodger et al., 1994). However, growing evidence from sequential studies on the histopathology of SAV disease from field samples and experimentally infected fish clearly demonstrated that the cardiac and skeletal muscle lesions are indeed significant findings in affected fish (Boscher et al., 2006; Boucher and Baudin Laurencin, 1996b; Castric et al., 1997; Christie et al., 1998; Desvignes et al., 2002; Ferguson et al., 1986a; Ferguson et al., 1986b; Graham et al., 2003b; Mccoy et al., 1994; McLoughlin, 1997; McLoughlin et al., 2002; McLoughlin et al., 1995; McLoughlin et al., 1996; Nelson et al., 1995; Poppe et al., 1989; Rodger et al., 1995). By excluding these important diagnostic criteria there is a significant chance of missing those fish still having various amounts of normal pancreatic acinar cells but nevertheless affected by the disease. Thus, fish in the acute phase with focal or diffuse pancreatic acinar cell necrosis, and fish in

the recovery phase with surviving or regenerated pancreatic acinar cells would be diagnosed as SAV-free. Clearly, this could have serious implication for the interpretation of the data on prevalence and severity of SAV in any study. This problem was addressed in a study from Boucher et al. (1995) who compared the susceptibility of rainbow trout, brown trout and Atlantic salmon to SAV1. From their infection trials only salmon could be diagnosed with SAV disease using the above criteria. However, both the rainbow trout and the brown trout evidently also became infected, and were significantly affected by the infection with SAV1, but since they had substantial amounts of intact pancreatic acinar tissue left SAV disease could per definition not be diagnosed.

In an attempt to standardize the diagnostic criteria for SAV1 disease, a summary of clinical signs, gross pathology and the range of histopathological features of infections with SAV1 in salmon in the British Isles was published by McLoughlin et al (2002). Here, it is acknowledged that it is a complex disease syndrome with varying degrees of pathology especially in the key organs exocrine pancreas, heart and skeletal muscle. The severity and distribution of lesions may vary but appear in a definite and consistent manner during the time course of an outbreak (acute, sub-acute, chronic and recovery). Clinical signs of SAV1 disease typically include lethargic fish staying close to the water surface near cage walls, with some fish resting or hanging on the side of the net-pens. Histopathological findings essentially involve different combinations of lesions in exocrine pancreas, heart and skeletal muscle. These histopathological lesions also applies to fish suffering from infections with SAV2 (sleeping disease, SD). The first publication on SAV2 briefly describes characteristic necrosis of the skeletal red muscle and inflammatory lesions in exocrine pancreas and heart of rainbow trout (Boucher and Baudin Laurencin, 1994). A more comprehensive study, where experimental crossinfections with SAV2 and SAV1 infected material in rainbow trout, demonstrated that the difference between SAV1 and SAV2 induced lesions in infected fish

were more quantitative rather than qualitative (Boucher and Baudin Laurencin, 1996b). Another common feature for infections with SAVs is the impaired swimming performance, which for SAV2-infected rainbow trout often is described as “sleeping behaviour”. Thus, the impact the different subtypes of SAV have on the infected hosts is very similar, and the differences between the diseases traditionally known as PD and SD seem to be related to the principal main hosts and their farming conditions, as well as their geographical origin; PD/SAV1 from salmon in seawater (British Isles and Norway) and SD/SAV2 from rainbow trout in freshwater (France).

In order to supply the traditional diagnostic criteria (clinical signs and histopathology) other confirmatory tests have been developed. Different virological assays involving cell-culture (usually CHSE-214) isolation of SAV from diseased fish can be used, but has traditionally been regarded as difficult to interpret because CPE is not always present or may be indistinct (Desvignes et al., 2002; **Paper II**; Nelson et al., 1995). To overcome the fact that CPE induced by SAV is not a reliable indicator of virus growth, immunostaining techniques using mAbs have been developed to detect the presence of virus in cell-cultures (Graham et al., 2003b; Jewhurst et al., 2004; Todd et al., 2001). Immunostaining using mAbs is also implemented in virus neutralization (VN) testing for detection of SAV neutralizing Abs in fish serum (Graham et al., 2003a). It should be stressed that although VN often is regarded as the gold standard for antibody detection, a positive VN test does not necessarily confirm the presence of the virus itself. Furthermore, in the acute phase of a SAV infection, before the fish sero-converts (< 10 days post infection (McLoughlin et al., 1996)), a VN test would be negative.

Villoing et al. (2000b) presented a two-step RT-PCR assay for detection of SAV2 RNA in naturally infected salmonids, which also proved useful for amplification of SAV1 in experimentally infected fish. A similar RT-PCR technique has also been used to detect SAV3

RNA from Norwegian salmon (**Paper I**; Nylund et al., 2003b). However, these RT-PCR protocols cannot discriminate between the SAV subtypes without further sequencing studies. Recently, real-time RT-PCR protocols using TaqMan® MGB probes have been developed for SAV which greatly improves the sensitivity and specificity of the standard RT-PCR, and makes it possible to differentiate between subtypes of SAV (**Paper III**). A less specific real-time RT-PCR assay using SYBR Green for detection of SAV in fish sera and tissues was later published by Graham et al. (2006). The increased specificity in a TaqMan probe assay compared to SYBR Green is a result of the different principles of detection. The dual-labelled TaqMan® probe is a single-stranded oligonucleotide that is complementary to a sequence within the target template (Figure 6), whereas the SYBR Green dye binds to any double-stranded DNA and is thus a sequence independent process.




Figure 6. The TaqMan® probe is a sequence-specific probe that contains a fluorescent reporter dye (R) attached to the 5' end and a nonfluorescent quencher moiety coupled to the 3' end (Q). a) Before the probe is cleaved by the *Taq* polymerase the quencher fluorophore reduces the fluorescence from the reporter fluorophore. b) After annealing of the Taqman® probe the *Taq* polymerase start to add nucleotides and removes the probe from the template DNA. c) This separates the quencher from the reporter and allows the reporter to emit detectable light.

Fish sera; neutralising Abs against SAV

An immunological response in salmon to infections with SAV was first suspected by McVicar (1987) who noticed that surviving fish from outbreaks of SAV were protected against subsequent infections of SAV. Experimentally, the first antisera to SAV were raised in salmon following infection with SAV-infected kidney homogenate (Houghton and Ellis, 1996). Passive immunization with these sera was found to give up to 100% neutralisation with no pathology developing in the challenged fish, and it was concluded that the protection to SAV was a result of the fish producing neutralising antibodies (Abs). McLoughlin et al. (1996) performed a virus neutralising (VN) test by incubating sera with 200 TCID₅₀ virus (SAV1) for 2h before inoculating into CHSE-214 cells with subsequent CPE readings. Neutralising Abs to SAV were first detected in experimentally i.p. infected salmon as early as 10 dpi, while the Ab production in cohabitants was detectable 11 days after (12-15C). Based on the above results and the study by Desvignes et al. (2002) the majority of fish would be expected to seroconvert 3-6 weeks post-exposure at temperatures 12-15C.

Neutralising Abs was also detected in salmon from field outbreaks of SAV3 in Norway (Christie et al., 1998), and it was shown that these field sera reacted with the reference Irish virus isolate F93-125 (i.e SAV1) (Nelson et al., 1995). This serological cross-reaction between sera from Norwegian salmon and an Irish virus isolate was later confirmed by McLoughlin et al. (1998), in a serological survey of the prevalence of neutralising antibodies to SAV in Irish, Scottish and Norwegian farmed Atlantic salmon. Experimental infection with SAV1 and SAV2 in both trout and salmon demonstrated the production of neutralizing Abs, and indicated full cross-neutralization (Weston et al., 2002). Serological cross-reaction with SAV1 was also detected in sera from SAV2-infected rainbow trout using an improved VN-test for Ab detection (Graham et al., 2003a). Here, an immunoperoxidase (IPX) based immunostaining using a monoclonal antibody (mAb) was developed for the detection of virus

growth in CHSE-214 cells, and was compared to the CPE-based VN detection in the original assay by McLoughlin et al (1998). Applying the IPX-VN assay on 353 farmed salmon and trout sera resulted in an overall seroprevalence of 25.7%, whereas all 188 sera collected from wild salmonids in freshwater localities in Northern Ireland were negative.

Polyclonal antisera and mAbs against SAV

The polyclonal mouse sera M4 was raised by Rowley et al (1998) and used to stain SAV1 infected CHSE-214 cells in combination with a biotin goat antimouse conjugate immunoperoxidase assay. Villoing et al. (2000a) produced a rabbit polyclonal antisera directed against a recombinant E2-protein from SAV2. When used in immunodetection of concentrated SAV2 virions it detected a single protein band of approximate molecular size of 47.5 kDa (Todd et al., 2001; Villoing et al., 2000a). This polyclonal E2 antiserum was later used in immunohistochemistry assays of infected pancreas, heart, muscle and brain with limited success compared to the RT-PCR protocol applied (Villoing et al., 2000b).

Monoclonal antibodies (mAbs) are currently utilized in many diagnostic procedures and are important tools in studies of pathogenesis. The first SAV specific mAbs were raised against whole virus of the Irish isolate F93-125; two mouse anti-SPDV monoclonal Abs (2D9 and 5D3) were produced and initially applied to infected CHSE-214 cells in combination with an immunoperoxidase detection assay (Rowley et al., 1998). These two mAbs, and the additional 1A9 mAb, also raised against F93-125, were used in a more comprehensive study by Welsh et al. (2000). They used the above three mAbs in various assays (indirect immunofluorescence (IIF) tests, RIPA with subsequent SDS-PAGE, immunodot blot), and demonstrated that 2D9 and 5D3 reacted with a single virus protein with a molecular mass in the 50-55 kDa range (Table 5). Based on the sizes of E1 (55 kDa) and E2 (50 kDa) analyzed by SDS-PAGE they concluded that 2D9 and 5D3 are reactive with an epitope of one of the two structural proteins.

Table 5. Monoclonal antibodies (mAbs) raised against SAV, with reference to their origin and application. Positive identifications of SAV isolates in the different applications are indicated in boldface, and negative identifications are underlined. The cited references are given as numbers for convenience, and corresponds to the numbering system of publications in the reference list.

mAb	Application										Reference			
	mAb raised against:		IAP		IF		Western Blot		RIPA			Other		
	SAV subtype (isolate)	Protein-domain	SAV subtype (isolate)	Protein-domain	SAV subtype (isolate)	cell location	Infective cell	Virus	<i>E. coli</i>	Putative protein			SAV subtype (isolate)	Putative protein
1A9	SAV1 (F93-1.25)	Whole virus	SAV1 (F93-1.25)	Whole virus	SAV1 (F93-1.25)	NC margin & cytoplasm	SAV1 (F93-1.25)	SAV1 (F93-1.25)	SAV1 (F93-1.25)	SAV1 (F93-1.25)	SAV1 (F93-1.25) ¹	—	141	141
2D9	SAV1 (F93-1.25)	Whole virus	SAV1 (F97-12)	Whole virus	SAV1 (F97-12)	NC margin & cytoplasm	SAV1 (F97-12)	SAV1 (F97-12)	SAV1 (F97-12)	SAV1 (F97-12)	SAV1 (F93-1.25)	E1 or E2 (50-55kDa)	112	112
	SAV1 (F93-1.25)	Whole virus	SAV1 (F93-1.25)	Whole virus	SAV1 (F93-1.25), F97-12, N2P6), SAV3 (NBP12)	NC margin	SAV1 (F93-1.25), F97-12, N2P6), SAV3 (NBP12)	SAV1 (F93-1.25), F97-12, N2P6), SAV3 (NBP12)	SAV1 (F93-1.25), F97-12, N2P6), SAV3 (NBP12)	SAV1 (F93-1.25), F97-12, N2P6), SAV3 (NBP12)	SAV1 (F93-1.25) ¹	SAV ²	141	112
1A9	SAV1 (F93-1.25)	Whole virus	SAV1 (P42P), SAV2 (S49P)	Whole virus	SAV1 (P42P), SAV2 (S49P)	NC margin & cytoplasm	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	130	112
	SAV1 (F93-1.25)	Whole virus	SAV1 (P42P), SAV2 (S49P)	Whole virus	SAV1 (P42P), SAV2 (S49P)	NC margin & cytoplasm	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	142	112
4H1	SAV1 (F93-1.25)	Whole virus	SAV1 (F93-1.25)	Whole virus	SAV1 (F93-1.25)	cytoplasm	SAV1 (F93-1.25)	SAV1 (F93-1.25)	SAV1 (F93-1.25)	SAV1 (F93-1.25)	SAV1 (F93-1.25)	E1 (53 kDa)	130	130
	SAV1 (F93-1.25)	Whole virus	SAV1 (P42P), SAV2 (S49P)	Whole virus	SAV1 (P42P), SAV2 (S49P)	NC margin & cytoplasm	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	Capsid (35 kDa and 30 kDa)	142	130
5A5	SAV1 (F93-1.25)	Whole virus	SAV1 (F93-1.25)	Whole virus	SAV1 (F93-1.25)	NC margin & cytoplasm	SAV1 (F93-1.25)	SAV1 (F93-1.25)	SAV1 (F93-1.25)	SAV1 (F93-1.25)	SAV1 (F93-1.25)	SAV1 (F93-1.25)	59	130
	SAV1 (F93-1.25)	Whole virus	SAV1 (P42P), SAV2 (S49P)	Whole virus	SAV1 (P42P), SAV2 (S49P)	cytoplasm	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	130	130
SD1	SAV1 (F93-1.25)	Whole virus	SAV1 (F93-1.25)	Whole virus	SAV1 (F93-1.25)	cytoplasm	SAV1 (F93-1.25)	SAV1 (F93-1.25)	SAV1 (F93-1.25)	SAV1 (F93-1.25)	SAV1 (F93-1.25)	SAV1 (F93-1.25)	59	130
	SAV1 (F93-1.25)	Whole virus	SAV1 (P42P), SAV2 (S49P)	Whole virus	SAV1 (P42P), SAV2 (S49P)	NC margin	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	130	130
SD3	SAV1 (F93-1.25)	Whole virus	SAV1 (F97-12)	Whole virus	SAV1 (F97-12)	NC margin	SAV1 (F97-12)	SAV1 (F97-12)	SAV1 (F97-12)	SAV1 (F97-12)	SAV1 (F97-12)	SAV1 (F97-12)	59	130
	SAV1 (F93-1.25)	Whole virus	SAV1 (F93-1.25)	Whole virus	SAV1 (F93-1.25)	NC margin	SAV1 (F93-1.25)	SAV1 (F93-1.25)	SAV1 (F93-1.25)	SAV1 (F93-1.25)	SAV1 (F93-1.25)	E1 or E2 (50-55kDa)	112	112
SAV1 (F93-1.25)	SAV1 (F93-1.25)	Whole virus	SAV1 (P42P), SAV2 (S49P)	Whole virus	SAV1 (P42P), SAV2 (S49P)	NC margin & cytoplasm	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	141	112
	SAV1 (F93-1.25)	Whole virus	SAV1 (P42P), SAV2 (S49P)	Whole virus	SAV1 (P42P), SAV2 (S49P)	NC margin & cytoplasm	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	130	112
SAV1 (F93-1.25)	Whole virus	SAV1 (P42P), SAV2 (S49P)	Whole virus	SAV1 (P42P), SAV2 (S49P)	NC margin & cytoplasm	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	142	112
SAV1 (F93-1.25)	Whole virus	SAV1 (P42P), SAV2 (S49P)	Whole virus	SAV1 (P42P), SAV2 (S49P)	NC margin & cytoplasm	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	SAV1 (P42P), SAV2 (S49P)	59	112

(Continues on next page)

Table 5. Continued

7A2	SAV1 (F93-125)	Whole virus	SAV1 (F93-125, F97-12, N2F6), SAV3 (N3P12)	cytoplasm	SAV	130	130
	SAV1 (F93-125)	Whole virus	SAV1 (F93-125, F97-12, N2F6), SAV3 (N3P12)			5	SAV ²
	SAV1 (F93-125)	Whole virus	SAV1 (P42P), SAV2 (S49P)			142	130
7B2	SAV1 (F93-125)	Whole virus	SAV1, SAV2	NC margin & cytoplasm	SAV	59	130
	SAV1 (F93-125)	Whole virus	SAV1 (F93-125, F97-12, N2F6), SAV3 (N3P12)			130	130
	SAV1 (F93-125)	Whole virus	SAV1 (P42P), SAV2 (S49P)			142	130
7C12	SAV1 (F93-125)	Whole virus	SAV1, SAV2			59	130
	SAV1 (F93-125)	Whole virus	SAV1 (F93-125, F97-12, N2F6), SAV3 (N3P12)	cytoplasm	SAV	130	130
II6	SAV2 (S49P)	Whole virus	SAV1 (P42P), SAV2 (S49P)			142	142
	SAV2 (S49P)	Whole virus	SAV1, SAV2			59	142
K16	SAV2 (S49P)	Whole virus	SAV1 (P42P), SAV2 (S49P)			142	142
	SAV2 (S49P)	Whole virus	SAV1 (F93-125, F97-12, N2F6), SAV3 (N3P12)			59	142
L2	SAV2 (S49P)	Whole virus	SAV1 (P42P), SAV2 (S49P)			142	142
	SAV2 (S49P)	Whole virus	SAV1, SAV2			59	142
17H23**	SAV2 (S49P)	E2	SAV1, SAV2	at cellular membrane		89	89
19F3	SAV2 (S49P)	nsP1	SAV1, SAV2	cytoplasm, punctate	SAV1, SAV2	89	89
3E17	SAV2 (S49P)	nsP3	SAV1, SAV2	irregular spots in cytoplasm	SAV1, SAV2	89	89
40D20**	SAV2 (S49P)	unknown	SAV1, SAV2	at cellular membrane	SAV1, SAV2	89	89
49K16	SAV2 (S49P)	E2	SAV1, SAV2	at cellular membrane	SAV1, SAV2	89	89
8A16	SAV2 (S49P)	nsP1	SAV1, SAV2	cytoplasm, dispersed	SAV1, SAV2	89	89
7I12	SAV2 (S49P)	nsP1	SAV1, SAV2	cytoplasm, more intense close to nucleus	SAV1, SAV2	89	89
78K5	SAV2 (S49P)	E1	SAV1, SAV2	cytoplasm, dispersed	SAV1, SAV2	89	89
4I16	SAV2 (S49P)	E2	SAV1, SAV2	at cellular membrane	SAV1, SAV2	89	89
51B8	SAV2 (S49P)	E2	SAV1, SAV2	cytoplasm, dispersed	SAV1, SAV2	89	89

* Immunoperoxidase-based neutralization assay (IPX-VN)

** Neutralizing mAbs

† Positive fluorescence for reference strain S49P only

‡ Dot-Blot

§ ELISA

Later, several additional mAbs have been raised against SAV1 and SAV2 whole virus (Morierte et al., 2005; Todd et al., 2001; Weston et al., 2002) and tested for reactivities against different subtypes of SAV. In general, the above mAbs show extensive crossreactivities with all tested subtypes of SAV (Table 5). Possible exceptions are the three mAbs 40D20, 4I16/I16 and 49K16/K16, all raised against the SAV2 isolate S49P, and which only reacts with SAV2 in IIF- and RIPA (Jewhurst et al., 2004; Morierte et al., 2005; Weston et al., 2002). However, in these studies positive staining reaction using the three mAbs was only observed with the reference SAV2 isolate, and not when field isolates of SAV2 were tested (Jewhurst et al., 2004; Weston et al., 2002).

Morierte et al. (2005) also mapped and characterized six additional mAbs raised against recombinant *E. coli*-expressed SAV2 proteins. These mAbs were directed against nsP1 (8A16, 19F3 and 71L2), nsP3 (3E17), E2 (51B8) and E1 (78K5), where the 3E17 mAb was able to discriminate between SAV1 and SAV2 in an IIF assay. Localization of some SDV proteins was suggested based on the staining pattern in infected cells for the different mAbs. Two of the nsP1-derived mAbs, together with the nsP3-derived mAb, showed positive reaction associated with type I cytoplasmic vacuoles (CPVIs). The staining pattern for the third nsP1-derived mAb was more dispersed in the cytoplasm. The SAV2 E2 protein was recognized either in the cytoplasm (51B8) or at the cellular membrane (4I16, 79K16 and 17H23), whereas the E1 protein reacted with mAb 78K5 in the cytoplasm. The latter mAb was also used for positive detection in an immunohistochemistry (IHC) assay from SAV2 infected red muscle and pancreas (Morierte et al., 2005).

While sera from survivors of previously SAV-infected fish have neutralizing Abs, it has been difficult to show any virus neutralizing activity from available SAV mAbs (Morierte et al., 2005; Todd et al., 2001). However, in Morierte et al (2005) neutralizing properties were

demonstrated from two mAbs (17H23 and 40D20), both directed against whole virus of the SAV2 type isolate S49P.

Epizootiology

Disease outbreaks caused by SAV1 and SAV3 are reported mainly between March-November, but can occur throughout the year. On average it takes 2-3 months post transfer to sea for SAV1 to infect a farm site in the British Isles (McLoughlin et al., 2002), but in Norway the average period from sea transfer to outbreak of SAV3 is 7-9 months (E. Brun, National Veterinary Institute, Norway, pers. comm.). However, outbreaks of SAV can occur as early as a 5-8 weeks after the smolt have been released into sea (Crockford et al., 1999). The duration of a SAV outbreak in a farm site can vary substantially; from 1-4 months in Ireland (McLoughlin et al., 2002), to an average of 10 weeks for Norwegian sites (E. Brun, National Veterinary Institute, Norway, pers. comm.). The severity of an outbreak and associated mortalities also varies greatly from only a few percent to more than 40% (McLoughlin et al., 2002). In summary, the onset, duration and severity of a SAV1&3 outbreak show considerable variation, and there are indications suggesting that this is related to water temperature, environmental factors such as feeding regime, smolt strain and regional differences. Outbreaks of SAV2 in rainbow trout in freshwater localities can be observed in fish of any age, but generally affect fish from 10-50g in spring when the water temperature is between 9-13°C (Boucher and Baudin Laurencin, 1996a). The mortalities associated with SAV2 are relatively low (5%), but as for SAV1 and SAV3 it may vary from a few percent to over 40% in some cases. A typical outbreak with SAV2 lasts for approximately 2 months. Indications that surviving fish from outbreaks of SAV develop a long-term protection to new infections was first noted by McVicar (1987), and this was later verified in experimental infection trials for both SAV1 and SAV2 (Boucher and Baudin Laurencin, 1996b; Houghton,

1994). Furthermore, acquired cross-protection against SAV1 and SAV2 was observed in *O. mykiss* after experimental infection with either SAV1 or SAV2 (Boucher and Baudin Laurencin, 1996b).

The subtypes of SAV are principally located to three different enzootic areas; SAV1 in British Isles, SAV2 in France and SAV3 in Norway (Figure 7). There are, however, some exceptions which complicate this clear-cut distribution. Recently, SAV2 has been found in Scotland and England (Branson, 2002; Graham et al., 2003b), but these incidents are considered a results of the import of SAV2 infected fish from France (Weston et al., 2005). SAV2 has also been isolated from diseased rainbow trout from Germany on one occasion, and is suspected, but not confirmed, in freshwater fish in Italy (Boscher et al., 2006). Unfortunately, no further information on virus and host origin is presently available. Kent and Elston (1987) described a disease condition compatible with SAV infection in pen reared Atlantic salmon in North America, but the true origin of the virus in this case-report can be questioned (see General discussion for details). Years later, Kibenge et al. (2000) reported a novel togavirus-like virus from salmon in New Brunswick (Canada), and were able to isolate and grow the virus in cell-cultures. A 330 bp PCR-amplicon from the togavirus-like virus cDNA was produced, but no nucleotide sequence is presently available for further identification of this virus. Since the virus-isolate was non-pathogenic in experimental infected salmon, it seems less likely that the togavirus-like virus can be assigned to SAV. Locally in Norway, SAV3 is now reported in new areas separated by more than 1000km from the enzootic focus in western Norway (Figure 8). However, these disease outbreaks with SAV3 in northern Norway can be traced back to transport of smolts from the enzootic area (**Paper II**), and as such is a clear parallel to the SAV2 incidences in Scotland and England (Graham et al., 2003b; Weston et al., 2005).




Figure 7. The subtypes of SAV are principally located to three different enzootic areas; SAV1 in British Isles, SAV2 in France and SAV3 in Norway

Vertical and horizontal transmission of SAV?

Successful transmission trials with SAV have been performed numerous times, mainly through intraperitoneal injections but also in cohabitant studies, thus demonstrating that horizontal infections with SAV can occur. Circumstantial evidence from salmon farms also points in the direction of horizontal spread of the virus between cages within single fish farms. In a artificial environment such as in fish farms the stocking densities can be very high, and horizontal spread of the virus within a single cage and between cages will be effective. However, the significance of horizontal spread of SAV between farm localities or regions is not clear. Here, transport of infected fish in well-boats seems to better explain the

observations of new SAV outbreaks in localities previously free of the virus (**Paper II**; E. Brun, National Veterinary Institute, Norway, pers. comm.).




Figure 8. The coastline of Norway. Locations where the SAV3 isolates were collected are indicated. The isolate prefix (SAV-) is left out for convenience. See **Paper II** for details on the different SAV isolates. Counties that are discussed in the text are indicated on the map as follows: F=Finmark, T=Troms, N=Nordland, SF=Sogn og Fjordane, H=Hordaland, R=Rogaland

The fact that Atlantic salmon populations from the entire northern Europe intermingle in their feeding grounds in the north Atlantic (Hansen and Jacobsen, 2003; Jacobsen and Hansen, 2001) should favour a possible horizontal spread of SAV subtypes. However, the absence of such crossinfections of SAV-subtypes suggests that horizontal spread in the wild is inefficient without involving a common vector, or situations where fish come in closer contact with each other. Closer contact between fish is obtained in a farming environment or in rivers in connection with spawning. Alternatively, it is possible that there are differences in susceptibility to infections with the SAV-subtypes in wild salmon from British Isles and Norway which prevent any crossinfections, although this seems less likely.

The question of whether vertical transmission of SAV is possible remains unclear. Earlier it was argued by several authors that horizontal spread was the only transmission route for SAV, but recently Castric et al. (2005) were able to re-isolate SAV2 from batches of egg and the 2 months old progeny from the experimentally infected broodfish. Similarly, it has been shown that SAV3 can be detected (by real time RT-PCR) in eggs and fry originating from naturally infected broodfish (A. Nylund, University of Bergen, Norway, pers. comm.). Vertically transmitted virus could also be the origin for the outbreak of SAV in salmon reported from North-America by Kent and Elston (1987) (see General discussion, page 47). If vertical transmission of SAV is a reality, it is quite possible that once SAV is introduced into the fish farming system a virus-isolate will be self-sustained due to the unnaturally high densities of susceptible hosts during all phases of the production cycle compared to the natural environment.

Reservoir for SAV?

Infection and transmission of SAV1 and SAV3 have through history been considered to occur in seawater, yet no good evidence exists for a marine reservoir. Circumstantial evidence has been presented by among others McVicar (1987), who mention numerous examples of a single smolt unit in Scotland providing fish which subsequently become affected in some sea farms but not in others. He also noted that there is a tendency that once a farm has become affected the disease re-appears with the yearly intake of new smolt. A marine origin of SAV is also argued in a study by Ferguson et al. (1986a) where fish from the same hatchery were transferred to two sites, but only developed the disease in the site where the disease was enzootic.

However, there are indications of both a freshwater reservoir and freshwater transmission for the virus subtypes. Firstly, SAV3 has been detected from freshwater smolts prior to the

transfer to sea (Nylund et al., 2003b, pers. obs.), which indicates either a vertical transmission or infection in the freshwater phase. Secondly, the geographically delimited disease problems in western Norway caused by SAV3 seem to be caused by a very homogenous virus reservoir. In the study on the molecular evolution of SAV3 a striking genetic homogeneity within the Norwegian sequence isolates was demonstrated, although the isolates covered a relatively large geographical area over a period of eight years (**Paper II**) (Figure 8). This suggests that some isolating factors exist that prevents further dissemination to new areas outside western Norway. As mentioned earlier the recent examples of SAV3 in northern Norway are believed to be a result of transport of SAV3 infected fish from smolt producers located in the enzootic region (**Paper II**), and hence should not be included in the natural geographical range of SAV3. For SAV3, the observed genetic homogeneity within the well defined enzootic focus is most likely explained by either extensive geneflow within the virus reservoir, or a common source of virus. A possible scenario with freshwater transmission and maintenance of SAV3 should therefore not be ruled out. In this phase of their lifecycle Atlantic salmon occur in much higher densities in the river systems than is the case in the marine phase, and would make in-contact (horizontal) virus transmission more probable. Whether such freshwater transmission of SAV involves an arthropod host or not is unknown.

Finally, it should also be noted that the kind of strict geographical distribution of the three different SAV subtypes is also a common feature for terrestrial alphaviruses, and is believed to reflect isolated host populations and viral geneflow within them (Brault et al., 1999; Kramer and Fallah, 1999; Lindsay et al., 1993; Mackenzie et al., 1995; Oberste et al., 1999; Strauss and Strauss, 1994; Weaver et al., 2004; Weaver et al., 1997). An original strict distribution of genotypes within ISAV is also proposed, and can be explained by a maintenance of virus in wild populations through local freshwater transmissions (Nylund et al., 2003a). However, a recent study on genotyping of ISAV isolates strongly suggests that

transport of ISAV infected salmon has resulted in a more widespread distribution of ISAV genotypes in Norway (Nylund et al., 2006). Fish viruses utilizing marine reservoirs such as VHSV and IPNV have generally widespread genotypes that are not restricted to enzootic foci (Benmansour et al., 1997; Einer-Jensen et al., 2004; Snow et al., 2004; Thiery et al., 2002; Zhang and Suzuki, 2004), and absence of such distinction reduces the probability of a marine reservoir for SAV.

Vector transmission of SAV?

An important issue concerning the dissemination of SAV involves the possible involvement of an arthropod vector, a common feature for other alphaviruses. Terrestrial alphaviruses, whose main host is often a bird or mammal, are arthropod borne (arbo-) viruses that are transmitted by an insect vector in which they are able to replicate. To date, the only known alphaviruses associated with the marine environment are SAV and the recently characterized alphavirus isolated from a parasitic louse (*Lepidophthirius macrorhini*) on the southern elephant seal (Linn et al., 2001). Although *L. macrorhini* is strictly a terrestrial arthropod and there is no conclusive evidence that it represents a true vector of the seal alphavirus, the results have fuelled speculations originally put forward by Weston et al. (1999) that an arthropod vector could be involved in the transmission of SAV in salmon. Obvious arthropod candidates for possible transmission of SAV1 and SAV3 would be the salmon louse *Lepeophtheirus salmonis* and/or *Caligus elongatus*, which are common ectoparasites on wild and farmed salmon in seawater. Indeed, SAV3 has been detected from *L. salmonis* by real-time RT-PCR collected from diseased fish (M. Karlsen, University of Bergen, Norway, pers. comm.), but it is not clear whether the source of virus is infected blood meals or actively replicating virus in the salmon louse. If *L. salmonis* were a transmission vector for SAV1 &3 the distribution of the different SAV genotypes should reflect the distribution of the *L.*

salmonis populations. Lice burden can be considerable on salmon in the feeding grounds in the North Atlantic and circumstantial evidence indicate that *L. salmonis* infestation occurs in these areas (Jacobsen and Gaard, 1997), which is further supported by recent studies demonstrating a lack of genetic differentiation of the North Atlantic *L. salmonis* populations (Tjensvoll et al., 2006). In contrast, the SAV subtypes have a geographically island like distribution with SAV1 in the British Isles, SAV2 in France, and SAV3 exclusively in Norway. Thus, no spread of subtypes occurs between these different geographical host populations, which in turn make the involvement of *L. salmonis* as a transmission vector for SAV unlikely.

Potential use of SAV in vaccinology

An advantage of the alphaviruses is that the RNA genome itself is infective to a host cell. This feature has been exploited by recombinant DNA technique where an infective full-length cDNA clone of the viral genome is synthesized. By conversion of the RNA genome into complementary DNA (cDNA), an intermediate can be generated that is amenable to genetic modification and which can subsequently be converted back – either *in vitro* or *in vivo* - into an RNA genome which is able to yield infectious virus. This process is known as ‘reverse genetics’. The positive-stranded RNA viruses, such as SAV, can be directly used for translation by the host cell machinery and initiate an infectious cycle. In the classical RNA-launched approach, cells are transfected with RNA transcripts made from the infectious cDNA clones, and the synthetic viruses are then recovered from these cells (Liljestrom et al., 1991; Rice et al., 1987). However, an alternative DNA-launched approach also exists that was first reported for poliovirus and has later been adapted for alphaviruses (Schlesinger and Dubensky, 1999). Here, synthetic viruses are generated by directly transfecting infectious cDNA clones into susceptible cells. Both of these approaches have been used to construct

infectious cDNA clones which have been invaluable in addressing many questions regarding the positive-sense RNA viruses. The cDNA full-length clone may be used as a vector for the expression of foreign proteins in eukaryotic cells, but it can also serve as a powerful tool in evaluating what effect substitutions, insertions or deletions have on virus replication (Frolov et al., 1996).

Recently, an infectious full-length cDNA clone of the Salmonid alphavirus (SAV2) was engineered by Moriette et al. (2006) in France. The 11,894 SAV2 genome was inserted into a transcription plasmid, pSDV, and effectively transfected into BF-2 cell-cultures with subsequent recovery of recombinant virus, rSDV. In vivo infectivity of rSDV in fish was confirmed by immersion of juvenile rainbow trout in a water bath with rSDV and two wild type virus isolates (wtSDV). All fish became infected with a virus titer of approx 10^7 PFU/ml for both rSDV and wtSDV. While the cumulative mortality after 60 days reached 78 % for wtSDV, no mortality was observed in the rSDV infected trout during the same period of time. The lack of pathogenicity of the rSDV was found to be associated with the temperature at which the viruses were produced; at 10°C rSDV was non-pathogenic to trout while it became pathogenic when grown at 14°C. The shift in the temperature was shown to be associated with the appearance of amino acid changes in the SDV structural proteins E2, 6K, and E1. In addition, when the rSDV-infected fish were challenged after 3 and 5 months with wtSDV and SAV1, no mortalities was observed. Thus, the protective properties of rSDV are promising for the application of the recombinant SDV as a potential vaccine against SAV. Also, the possibility for the rSDV to express foreign protein was explored. Here, a rSDV encoding heterologous protein representing more than 20% additional sequence was successfully transfected and expressed, which suggests that the established pSDV system also has potential as an effective expression vector in salmonids.

2 AIMS OF THE PRESENT STUDY

In Norway, at the time when the project started (2001), little was known about the virus responsible for the mortalities allegedly caused by the disease known as PD. Initially, an important goal was to develop more sensitive and specific diagnostic tools for this virus, since a clear-cut diagnosis often was precluded by similar clinical and histopathological lesions associated with other disease conditions. A strategy involving PCR detection of the viral genome was decided as the method of choice. It soon became evident that the virus from diseased fish in Norway was genetically different from SAV1 in the British Isles. Therefore, the project was extended to include a molecular characterisation of the Norwegian subtype of SAV.

Thus, the specific aims of the present study were to:

- Genetically characterise the Norwegian subtype of SAV.
- Develop a sensitive and specific test for the detection of SAV, and use this to
- Study the geographical distribution of SAVs in Norway.

3 OVERVIEW OF PAPERS

Paper I. This work presents the first molecular description of the virus responsible for pancreas disease (PD) in Norway. The virus was isolated from moribund fish suffering from pancreas disease (PD) from different locations in western Norway; one isolate originated from rainbow trout (*Oncorhynchus mykiss*), whereas the remaining three were collected from farmed salmon (*Salmo salar*). Based on analyses of the near full-length nucleotide sequence it is evident that these isolates represent a single entity, which is significantly different compared to the other members of the Salmonid Alphavirus (SAV). This contradicts the

previous hypothesis that PD in farmed salmonids in Norway is caused by the same virus as that described in the British Isles; Salmon Pancreas Disease Virus (SPDV). The new virus strain (SAV subtype 3) seems to be exclusive for PD isolates in Norway and is per date not located elsewhere.

Paper II. The classification of the alphavirus species SAV is now comprised of at least three subtypes 1-3; SAV1 isolated from salmon *Salmo salar* in Ireland and the British Isles, SAV2 isolated from rainbow trout in France and the British Isles, and new SAV3 described in **Paper I**. The present paper has investigated the phylogenetic relationships among 20 SAV3 isolates, based on a 1221-nt long segment covering part of the capsid gene, E3, and part of the E2 gene, that were collected over a period of eight years. The isolates covered a large geographical area from Rogaland in the south to Finmark in northern Norway. All isolates were of the SAV3 subtype and supports the notion in **Paper I** that this is the only subtype of SAV occurring in Norway. Furthermore, the results revealed genetic homogeneity among SAV3 isolates and a low substitution rate suggesting that some mechanism(s) exist to stabilize the molecular evolution of SAV3. The genetic stability of SAV3 was also studied in CHSE-214 cells. Sequencing of the SAV3 genome (11530 nt) after 20 passages revealed only four nucleotide substitutions, all resulting in amino acid substitutions. One of these substitutions, serine to proline in E2 position 206, was also found to have occurred in field isolates.

Paper III. The recent discovery that pancreas disease in Norway is in fact caused by a new and distinct subtype of salmonid alphavirus (**Paper I and II**), exclusively found in Norway, has advocated the need for better diagnostic tools. In the present paper, three real-time PCR assays for all known subtypes of salmonid alphavirus have been developed; the Q nsP1 assay is a broad-spectrum one that detects RNA from all subtypes, the Q SPDV assay specifically

detects the salmon pancreas disease virus subtype, and the Q_NSAV assay only detects the new Norwegian salmonid alphavirus subtype. The results demonstrated the assays to be highly sensitive and specific, detecting <0.1 TCID₅₀ of virus stocks, and were reproducible over a wide range of RNA input. Thirty-nine field samples were tested in triplicate and compared with traditional RT-PCR. Overall, the real-time assays detected 35 positive compared to 29 positives in standard RT-PCR, and were thus shown to be more sensitive for detecting salmonid alphaviruses in field samples. The real-time PCR assays are excellent tools for monitoring or screening purposes, and have great potential in future quantitative studies of SAV.

4 GENERAL DISCUSSION

The aims of this thesis has been to supplement the present diagnostic tools for SAV and, by implementing the new and improved detection method, try to get a better overview and understanding of the distribution of SAV in Norway. In the course of this study it became evident that the Norwegian isolates of SAV were unique compared to the two subtypes of SAV previously described from Ireland and France. Hence, a genetic characterisation of the Norwegian SAV subtype was imperative and became a central part of the thesis.

Genomic sequence diversity within SAV

Analysis of the genomic sequences from the four Norwegian virus isolates in **Paper I** show that they possess a genome organization that is identical to that observed for the other two SAV isolates, SAV1 and SAV2 (Weston et al., 2002), and for mammalian Alphaviruses (Strauss and Strauss, 1994). In summary, the body of evidence from phylogenetic analysis based on the amino acid or nt sequence of different virus isolates available in the Genbank shows that these viruses constitute a distinct species (Salmonid Alphavirus, SAV) within the genus *Alphavirus* of the family *Togaviridae* (Weston et al., 2002; present study) (Figure 9). SAV can further be divided into the three subtypes SAV1, SAV2 and SAV3 (**Paper I**; Weston et al., 2002), and these subtypes seem to have distinct geographical distributions; SAV1 has a geographical basis in the British Isles, SAV2 originates from France but is now also present in the British Isles and Germany, and SAV3 which is enzootic to Norway (**Paper II**). A recent addition to the sequence variation within SAV was reported by Weston et al. (2005) in a sequence study on sequences of E1 and nsP4 gene fragments from SAV isolates originating from British Isles, France and Norway. Interestingly, they identified a variant of SAV1 isolated from salmon in Scotland (Western Isles), which showed consistent sequence differences from all the three subtypes of SAV, but was more closely




Figure 9. The phylogenetic position of the SAV3 isolates (SavH20/03, SavSF21/03, SavH10/02 and N3-1997) in relation to other salmonid Alphaviruses (SAV) and mammalian Alphaviruses. The evolutionary relationship is presented as a maximum likelihood tree based on alignment of non-structural polyproteins amino acid sequences from selected members of genus Alphavirus. The scale bar shows the number of amino acid substitutions as a proportion of the branch lengths. EEE=eastern equine encephalitis, VEE= Venezuelan equine encephalitis WEE=western equine encephalitis.

related to SAV1. The evolutionary significance of this variant of subtype 1 SAV is uncertain, and so far such intermediate sequence variants are not reported for SAV2 or SAV3. However, this clearly demonstrates the need for more sequence isolates of SAV in order to gain better insight into the molecular diversity of SAV. This is exemplified by the acknowledgement of the new Norwegian subtype of SAV (**Paper I**), a virus that has for different reasons been erroneously designated as SAV1, but is now regarded as the only subtype circulating in Norway.

A new addition to the sequence diversity of SAV may come from North America. If the disease condition reported from Atlantic salmon in Washington state by Kent and Elston (1987) is caused by SAV, and their assumptions that the virus is of local marine origin, it is quite possible that this could represent yet another subtype of SAV that is different from the European subtypes. However, it seems peculiar that this case-report by Kent and Elston (1987) is the sole record of infection of salmonids in North America, and has never subsequently been observed in this region hereafter. On the contrary, it seems more probable that the imported salmon eggs from Scotland and Norway, from which the diseased fish were hatched and reared from, is the source of the virus. If this were the case then the virus causing the disease condition in Kent and Elston (1987) could be assigned to SAV1 or SAV3. Not only would this be an example of the importance human activities have on the spread and distribution of diseases, but it also indicates that vertical transmission within SAV may occur. A novel togavirus-like virus has also been isolated from fish suffering from ISA in New Brunswick, Canada (Kibenge et al., 2000). However, the experimental infection trials and sequence data deposited in the Genbank are not compatible with a SAV aetiology.

Two other examples of introduction of SAV to new areas as a result of human activities are known; import of SAV2 infected rainbow trout from France to two sites in England and

Scotland (Branson, 2002), and transport of SAV3 from smolt producers in Western Norway to marine sites in Northern Norway (**Paper II**). Although not conclusive, the latter case study is believed to be a result of well-boat transport of SAV3 infected smolts to locations with no prior history of SAV. This is supported by the observation that the genotype sequence from these recent outbreaks in northern Norway is very similar or identical to the isolates from Western Norway at least 1000 km to the south (**Paper II**).

RNA viruses commonly have substitution rates in the range of 10^{-3} to 10^{-5} misincorporations per nt copied (Drake and Holland, 1999), which for SAV should result on average at least one substitution introduced per genome replication. Although the SAV3 isolates herein is diverse with respect of time and space, the sequences show surprisingly little variation as demonstrated in the calculated evolutionary rate of 1.7×10^{-4} nt substitutions/site/year. As previously speculated this could be a result of stabilizing selection often seen in arboviruses that replicate in two alternating hosts, and could therefore indicate the presence of a vector for SAV3. However, it was recently shown that ISAV, a salmonid virus without vector replication, has even lower evolutionary rates than SAV3 (Devold et al., 2006; Nylund et al., 2006), a result that may question the hypothesis of a vector transmission for SAV3.

The low evolutionary rates for SAV3 only reflects the sequence data used in the analysis, and including gene fragments other than these used in the present study (capsid, E2 and E3) may result in different evolutionary rates. It is also possible that the low evolutionary rates for SAV3 is an artefact resulting from selective sampling, since all our sequence isolates are collected from a relatively homogenous host population (i.e farmed salmonids in seawater). This biased sampling also applies to the other SAV subtypes; to date, there is no record of SAV from wild fish and all isolates and sequences originate from farmed salmonids. Thus, the question arises whether the existing sequence diversity of SAV represents the true diversity, or perhaps only mirrors the recycling of a few selected isolates that is maintained and

multiplied in the farming industry in the respective countries? If the sequence diversity reported from Norwegian SAV isolates is the true diversity for SAV3, then this could indicate a recent introduction of SAV to Norway. An introduction of SAV (for instance through import of salmonids from other countries) could result in an establishment of a new SAV population carrying only a small fraction of the variation from the original SAV population (quasispecies). The resulting genetic diversity from such a genetic bottleneck will be low, since the founder population only consists of a limited number of virus individuals (Manrubia et al., 2005).

Real time PCR as a screening- and diagnostic tool

The success in obtaining wild-type isolates of SAV is very much dependent on the sensitivity of the screening tools, locality, life history stage of the fish host, prevalence and amount of virus in infected tissue, tissue tropism and number of samples examined. Any new field isolates from a non-farming site would also give important indications on natural SAV reservoirs. Some effort has been made to screen wild population of salmon and trout for SAV using the IPX-based VN-assay described by Graham et al. (2003a). Sera from approximately 400 wild salmonids from Ireland and 42 from Norway have been tested, but none were positive (Graham, 2005; Graham et al., 2003a). This could imply that wild fish cannot be considered an important reservoir of SAV infection for farmed populations. It is, however, a possibility that serological testing is not sufficiently sensitive to detect subclinical or latent carriers of SAV. Moreover, the occurrence of SAV in wild fish may very well be delimited/defined in time and space, which makes it crucial to know when and where to sample fish to increase the likelihood of retrieving new wild-type isolates of SAV. Since we do not know any details on SAV in wild fish this can only be speculated on, but any

information regarding the anamnesis of outbreaks of SAV may indicate or be decisive for a sampling strategy.

A sensitive tool is needed when screening subclinical amounts of SAV. The TaqMan based real-time RT-PCR protocol developed for detecting RNA from all subtypes of SAV should prove useful (**Paper III**). It was demonstrated that the Q_{nsP1} assay was 10-100 fold more sensitive than standard RT-PCR on all virus stocks tested, and when applying this test on field samples the number of positive fish increased by 15% compared to standard RT-PCR. How the Q_{nsP1} assay performs compared to the IPX-VN assay applied in the literature (Graham, 2005; Graham et al., 2002; Graham et al., 2003a) is not known, but the relationship between presence of neutralizing Abs and Ct-values (i.e amount of viral RNA) from real-time RT-PCR assays should be examined in detail. Ideally, a combination of serology and real-time RT-PCR testing should be performed for each fish sampled, which should provide more detailed information on the viraemic stage of the fish. If both the IPX-VN and Q_{nsP1} assays were negative in a combined test then it is highly probable that the sample is negative for SAV. When both IPX-VN and Q_{nsP1} are positive then a current infection with SAV is present. A situation where the IPX-VN is negative but with low Q_{nsP1} values also represent a current infection, but is in an early stage of infection before the fish seroconverts (approx. two weeks). Last, if the IPX-VN is positive and Q_{nsP1} is negative this would represent either a previous infection where the hosts immune response (neutralizing Abs) have cleared the virus, or a persistent or latent infection in carrier fish with low, undetectable virus numbers. The increased sensitivity (and specificity) of the Q_{nsP1} assay may prove particularly useful for addressing the important question whether SAV can exist as a latent or persistent infection in the host. Persistent infection of SAV has been demonstrated in experimental infection trials in salmon (unpubl. results) and is discussed in more detail below.

Diagnosis of diseases caused by SAV (PD and SD) has previously, and is still mainly based on clinical signs in combination with histopathological findings. Also, detection of specific antibodies in fish sera (see above) and virus isolation in cell cultures have been applied to verify the aetiology (Graham et al., 2003a; Jewhurst et al., 2004), but none of these methods are capable of discriminating between the different SAV subtypes. Moreover, the presence of virus-specific antibodies in serum only states that the fish has been exposed to SAV minimum 10-14 days prior to sampling, and thus provide only limited information on the viraemic status of the fish. Presently, there is a large panel of mAbs for direct detection of SAV antigens (Table 5) but since most of them show extensive cross-reactivities with the other subtypes this probably makes them unsuitable for distinguishing subtypes of SAV. However, some of the mAbs capable of reacting with all three subtypes of SAV should have the potential for a diagnostic test common for all SAV. To overcome the fact that the prevailing diagnostic methods were not sufficient to rapidly distinguish between the different pheno-/genotypes, standard RT-PCR based protocols were developed for SAV (**Paper I**; Nylund et al., 2003b; Villoing et al., 2000b). Combined with sequencing of the RT-PCR amplicons this greatly enhanced the sensitivity and specificity of detecting SAV in tissues. Further refinement of this methodology is presented in **Paper III** where a TaqMan based real-time RT-PCR protocol is described in detail. To date, this method represents the most sensitive, specific, labour- and time saving method for identification of viral RNA of any SAV subtype, and has a great potential as a diagnostic tool in fish medicine. It can also be used to estimate the viral RNA load in any tissue, either as absolute quantification or relative quantification. In most cases it is sufficient to merely document the relative changes of SAV-templates between varying experimental conditions (Bustin, 2000; Mackay et al., 2002; Pfaffl, 2001). This can be achieved by simultaneously monitoring a non-regulated reference target; either internal or externally added.

As for all diagnostic tests the type of tissue samples used will influence/have great impact on the test results, and it is of the utmost importance to have some knowledge of the tissue and organ distribution of the pathogen in question. To address this issue, the newly developed real-time RT-PCR assays for SAV are ideal to monitor and relative quantify viral RNA from different tissues in salmon during outbreaks of SAV. In an experimental infection of salmon with either SAV1 or SAV3 it was possible to detect viral RNA in fish tissues at all stages of the disease, including previremia, for as long as 190 days after i.p injection (Andersen et al., submitted). The infected fish showed no clinical signs of disease during this viral persistence, which indicated that surviving salmon became asymptomatic carriers of SAV. The temporal relative changes in SAV load in the experimentally infected salmon were normalized to both an internal control gene (Elf-1, (Olsvik et al., 2005)) and external added control (Influenza A RNA). The results from the Q_{nsP1} assay also show that the pseudobranch and heart tissue (ventricle) were best suited for diagnostic purposes regardless of disease status. On the other hand, pancreatic tissue was considered unsuitable for real-time RT-PCR testing of SAV RNA. Moreover, the observation of a high percentage of SAV positive gill tissues in the experimentally infected fish should enable non-lethal gill biopsies in future screening of valuable broodstock fish and/or wild salmonid stocks.

As pointed out in **Paper II** the reliability of cell culture detection of SAV is hampered by the fact that virus-induced CPE is weak or not always present. This problem can be overcome by simply using real-time RT PCR detection and quantification of SAV, making the subjective interpretation of the presence/absence of CPE in the cell-culture redundant in terms of virus replication. A protocol for the relative quantification of SAV in CHSE-214 and ASK cells using the Q_{nsP1} assay has now been developed (unpubl. data), where the Q_{nsP1} Ct-values from a fixed number of cells are normalized to the internal Elf-1 Ct-values and an externally added reference gene. The initial 10²-10³ fold increase in virus production in the cell-cultures

(ASK and CHSE-214) stabilizes after 48 hours, and remains constant thereafter until a slight decrease is observed between 192 and 336 hours after infection. Parallel to the monitoring of virus production with time, the normalized expression profiles of the type I interferon α (IFN- α) and the GTP-ase Mx protein were recorded. In both ASK and CHSE-214 cells IFN- α and Mx were upregulated, with a slight lag for the Mx response. Interestingly, the upregulation of IFN- α /Mx was significantly higher in the SAV infected ASK cells compared to the CHSE-214 cells, and was also accompanied with lower virus production in ASK. These cell responses to SAV infection may be attributed to the host (salmon) from which the virus isolate was originally isolated, assuming that SAV3 is better adapted to infect Atlantic salmon kidney cells rather than Chinook salmon embryo cells. Also, since ASK cells are macrophage-like cells they possibly produce higher amounts of IFN and Mx than CHSE-214 cells which are derived from embryonic cells.

In summary, the Q-nsP1 assay has proven to be a specific and sensitive tool for the detection of SAV RNA, and has a wide range of applications in *in vitro* studies, during experimental infection trials, for screening purposes and as a diagnostic tool. As a screening tool the Q_nsP1 assay offers a convenient means of studying potential reservoirs and vectors for SAV. The time and labour savings combined with the assay's high sensitivity and specificity enable large sets of samples to be analyzed in a short time. These are attractive features since the expected low prevalence and intensity of infection of SAV in naturally occurring populations of fish and/or potential vector species necessitates large sample sizes to be screened.

SAV; differential diagnostics

The reason why new and improved diagnostic tools are needed is because a diagnosis of SAV disease based on clinical signs and histopathology is not always straightforward. In Norway there are at least three important differential diseases which may preclude a clear-cut

diagnosis of SAV disease; IPN, CMS and HSMI. An overview of important clinical signs and histopathological features for the three diseases is given in Table 6. It appears that SAV disease, HSMI and CMS have a slightly different geographical distribution in Norway; SAV seem to be enzootic to western Norway (Rogaland, Hordaland and southern parts of Sogn og Fjordane) (Figure 8), while the majority of HSMI and CMS outbreaks have an overlapping distribution in mid Norway (Møre og Romsdal and Sør-Trøndelag). The IPNV is widespread in the farmed Atlantic salmon industry (Jarp et al., 1995), and can be readily isolated from diseased and apparently healthy fish. On the other hand, SAV is known to be notoriously difficult to isolate, especially in later stages of the disease. IPNV causes a similar pancreatic pathology as for SAV disease in salmon post-smolts but can in most cases be discriminated from PD on the basis on gross clinical signs, as well as the usual presence of catarrhal enteritis and the absence of cardiac and skeletal muscle lesions. Additionally, IPNV titres of 10^6 - 10^9 TCID₅₀/g tissue and identification of IPNV using immunohistochemistry can be used to confirm an IPN disease (McLoughlin, 1997). Still, it should be noted that although heart and skeletal muscle lesions are rare features in IPN, mild cardio- and skeletal myopathy have been associated with IPN (McLoughlin, 1997).

Heart (compact and spongy layer) and skeletal muscle lesions are also the main histopathological features of fish suffering from HSMI, but this disease does not exhibit any necrosis of exocrine pancreas commonly found in SAV affected fish. Additional lesions in the liver with multifocal necrosis of hepatocytes are also associated with HSMI (Kongtorp et al., 2004a), a feature only rarely reported from SAV diseased fish (McLoughlin et al., 2002; Munro et al., 1984). As opposed to SAV and HSMI, only limited skeletal muscle lesions are described from fish with CMS (Ferguson et al., 1990). The myocardial lesions typically found in fish with CMS are not always easily differentiated from the histopathological changes

Table 6. A summary of clinical signs and histopathological lesions associated with heart and skeletal muscle inflammation (HSMI), cardiomyopathy syndrome (CMS), and infections with Salmonid alphavirus (SAV) and Infectious pancreas necrosis virus (IPNV) in Atlantic salmon, including indirect or direct identification methods of SAV and IPNV. The cited references are given as numbers for convenience, and corresponds to the numbering system of publications in the reference list. The publications confirming the presence of a specific clinical sign or histopathological lesion are indicated in boldface. The publications confirming the absence of a specific clinical sign or histopathological lesion are underlined. In publications where these clinical sign or histopathological lesion are found inconsistently, the cited references are indicated in italics.

	SAV						IPN	HSMI	CMS	Ref.
	Acute 0-10 days	Sub-acute 10-21 days	Chronic 21-42 days	Recovery/carrier >42 days	Ref.	Ref.				
<u>Histopathology</u>										
Exocrine pancreas lesions										
Focal acinar cell necrosis	+ 82	+/- 82	- 82	- 82	- 82	+ 82	- 82	- 28, 64, 65	- 65	65
Diffuse acinar cell necrosis	+ 82	+/- 82	- 82	- 82	- 82	+ 82	- 82	- 28, 64, 65	- 65	65
Significant loss of acinar cells	- 82	+ 82	+ 82	+/- 82	- 82	+ 82	- 82	- 28, 64, 65	- 65	65
Periacinar tissue fibrosis	- 82	- 82	+/- 82	- 82	- 82	+ 82	- 82	- 28, 64, 65	- 65	65
Regeneration of acinar cells	- 82	- 82	+ 82	+ 82	- 82	+ 82	- 82	- 28, 64, 65	- 65	65
Heart lesions										
epicardium	+/- 83, 82	+/- 83, 82	+/- 82	+/- 82	- 82	+/- 82	+ 81, 82	+ 65, 28	+ 29, 65	29, 65
compact myocardium	+ 83, 84, 23, 82	+ 31, 93, 83, 84, 23, 82	+/- 31, 93, 83, 84, 23, 82	+/- 31, 93, 83, 84, 23, 82	- 93, 82	+/- 93, 82	+ 81, 82	+ 65, 28	- 29, 65	29, 65
spongy myocardium	+ 83, 84, 23, 82	+ 31, 93, 83, 84, 23, 82	+/- 31, 93, 83, 84, 23, 82	+/- 31, 93, 83, 84, 23, 82	- 93, 82	+/- 93, 82	+ 81, 82	+ 65, 28	+ 29, 65	29, 65
endocardium	+ 82	+ 82	+/- 81, 82	+ 82	- 82	+/- 82	+/- 82	- 28	+/- 29	29
Skeletal muscle lesions										
red	- 23, 82	+/- 93, 84, 23, 82	+/- 93, 84, 23, 82	+/- 93, 84, 23, 82	- 93, 82	+/- 93, 82	+/- 81, 82	+/- 65, 64, 28	+/- 29, 65	29, 65
white	- 23, 82	+/- 93, 84, 23, 82	+/- 93, 84, 23, 82	+/- 93, 84, 23, 82	- 93, 82	+/- 93, 82	+/- 81, 82	+/- 65, 28	+/- 29, 65	29, 65
Liver lesions										
Multifocal hepatocytic necrosis	+/- 83, 82	+/- 83, 82	+/- 83, 82	+/- 83, 82	- 82, 83	+/- 82, 83	+ 81, 82	+ 28, 64, 65	+/- 29, 65	29, 65

(Continues on next page)

found in SAV diseased fish and HSMI, although lesions seem to be restricted to the spongy myocardium in CMS (Kongtorp et al., 2004a).

Some of the clinical signs for SAV infections, CMS, IPN and HSMI are also considered as valuable indicators for a disease outbreak. For SAV, early clinical signs include a sudden decrease in feeding response, with fish that gradually become lethargic and are unable to maintain a normal horizontal position. The affected fish tend to congregate in the cage corners close to the surface in a slightly upright position, with some fish falling down to rest on the net sides or bottom. SAV infections typically affect post-smolts some 5-9 months after sea transfer in May/June and September /October, although there seems to be a change towards infections occurring throughout the year in fish of all sizes. Most of these clinical features are shared by fish affected with HSMI; appetite loss and sluggish behaviour where the affected fish typically reside close to the water surface near cage walls facing the sea current (Ferguson et al., 2005; Kongtorp et al., 2004b). Furthermore, disease outbreaks with HSMI are most common in post-smolts 5-9 months after transfer to sea. A possible difference between the clinical signs in SAV and HSMI seem to be the reduced appetite observed early in a natural outbreak of SAV, a feature not always reported from HSMI fish (Kongtorp et al., 2004b). Reduced appetite does not seem to be a prominent clinical feature in post-smolts affected with IPN, nor do they exhibit notable changes in behaviour. Furthermore, infections with IPNV typically affect post-smolts during their first three months after sea transfer (< 1 kg). Fish suffering from CMS show no obvious signs of clinical disease, especially in its acute form; only relatively large (2-4 kg) and otherwise seemingly healthy fish are affected, with no loss of appetite or abnormal swimming behaviour.

In summary, the respective characteristic clinical signs and histopathological profiles for IPN, HSMI and CMS are in most cases sufficient to differentiate between them from SAV-infections if they appear singly in fish from natural outbreaks and in its typical form. Potential

difficulties in diagnosing SAV may arise if SAV pathologies and/or IPN, HSMI and CMS occur in atypical forms or as concurrent infections. This is especially relevant considering that IPNV traditionally has been much easier to detect and isolate than the SAV, and that the pancreas lesions of the two diseases are very similar. As a consequence the prevalence and significance of SAV has probably been underestimated in the past years at the expense of IPN (similar pancreatic lesions). Implementing the Q-nsP1 real-time assay in studies of problematic case-studies could easily clarify the presence or absence of SAV in the diseased fish.

Diseases caused by SAV; - are they different?

Today, we know that there are at least three subtypes of the Salmonid alphavirus causing mortalities in salmonid farming (**Paper I**), but are they manifested as three different diseases? In a historical perspective, pancreas disease has been used to denote disease conditions caused by severe infections of SAV in salmon farming in the British Isles and Norway, whereas sleeping disease is caused by SAV infection in rainbow trout farming in France. However, the recent discovery of SAV3 somewhat complicates this picture because we now have three different subtypes of SAV, but there are only two names for the diseases caused by these subtypes. Although PD always has been, and still is, treated as a uniform disease across Europe (the British Isles and Norway), it is important to emphasise that the SAV3 is in fact equally distant from SAV1 as SAV2 (**Paper I**), and should be acknowledged as a separate disease agent different from SAV1 (and SAV2). In terms of disease-causing abilities, previous descriptions of SAV1 and SAV3 are however not sufficiently different to separate them as distinctive diseases, but more studies of pathogenesis will be needed to clarify this issue. Such comparative studies of the biological properties of SAV should not only include SAV1 and SAV3, but also SAV2 because of the striking histopathological similarities of SD

(SAV2) and PD (SAV1, SAV3). Despite the fact that PD and SD share identical histopathological lesions, they have always been mentioned and treated as two distinct and separate diseases. Principal hosts are rainbow trout for SD (*O. mykiss* > *S. salar* > *S. trutta*) and Atlantic salmon for PD (*S. salar* > *O. mykiss*), but cross-infections can occur (Boucher et al., 1995; Olsen and Wangel, 1997; Villoing et al., 2000b). SD was initially described from rainbow trout and given its name based on the peculiar behaviour of affected fish. The origin of the name PD, on the other hand was based on the severe exocrine pancreas lesions observed in diseased Atlantic salmon in the original description by Munro et al. (1984). The two disease conditions were thus named based on two very different criteria; a) clinical behaviour ->SD, and b) histopathological lesion ->PD. However, the histopathology of the two diseases is strikingly similar, with identical lesions in the key organs; exocrine pancreas, heart muscle and skeletal muscle. These are all lesions that would classify the two diseases together rather than separating them. This is also supported by Boucher et al. (1996) who concluded that the difference between PD and SD lesions in experimentally infected fish were more quantitative rather than qualitative supports this view.

At first glance the clinical signs observed in fish with SD or PD seem quite different; SD is characterized by the behaviour of affected fish who tend to “rest” at the bottom of tanks, while lethargic PD fish are seen aggregating in the water surface facing the cage wall or corners. Although these are the typical clinical observations referred to for SD and PD, they are not contradictory. The characteristic “sleeping” condition in SD affected fish can only be observed in tanks or basins where the bottom surface is visible. When handled they will swim for a very short time, simply as an escape response, before returning to the bottom, again lying on their sides. In deeper or muddier farm basins any fish lying on their sides is not readily seen, and this behaviour is thus overlooked. In these cases only the lethargic fish staying near the surface waters are observed. This latter example is very similar to the typical

behaviour observed in clinically diseased post-smolts in net-pens during a natural PD outbreak. Here, lethargic PD fish tend to stay close to the water surface near cage walls, and some fish are seen resting or hanging on the side of the net-pens. Furthermore, McLoughlin et al. (2002) pointed out that PD fish can appear dead on the bottom of the cage, but swim away when handled, an observation identical to the “sleeping” behaviour seen in SD affected rainbow trout. Apparently lethargic fish lying on their sides on the net floor is also observed from fish suffering from HSMI (Ferguson et al., 2005), indicating that this behaviour is not exclusive or otherwise characteristic for SAV2 infections. Thus, the differences in the disease appearance of PD and SD, if there are any, would then simply reflect the different farming conditions for the affected hosts from which SD and PD are commonly reported from. Hypothetically, if extensive farming of salmon and rainbow trout were to overlap in time and place a situation where either PD or SD or both co-occurred, a confirmatory SD or PD-diagnose based on clinical signs would be impossible to make.

In summary, the behaviour, clinical signs and histopathological lesions in salmonids suffering from PD (SAV1, SAV3) and SD (SAV2) are remarkably similar and as disease conditions they should be considered identical. Therefore, an umbrella term for the historical names PD and SD, which merely refers to the virus species involved rather than the clinical signs (“sleeping disease”) and histopathological lesions (“pancreas disease”) is proposed; Salmonid Alphavirus Disease (SAVD). The term SAVD in salmonids would then include the same histopathological lesions in the key organs exocrine pancreas, heart- and skeletal muscle as previously described from the former SD and PD, but the clinical signs would be more detailed and include the full range of behavioural characteristics from both PD and SD. Because clinical signs and histopathology alone cannot unequivocally discriminate between subtypes of SAV (see above) a more correct term would be to use SAVD, and when needed (and if possible), a more specific assignment of the disease agent (SAVD subtype-1, -2 or -3)

may be given. At present, the only way to further assign SAVD to one (or more) of the three subtypes of SAV, is to perform specific tests such as real-time RT-PCR and/or sequencing studies. However, introducing a new term common for PD and SD present some drawbacks; PD and SD are now well-established and commonly accepted labels or names for these disease conditions, and it can be argued that by introducing a new term (SAVD) only contribute to the confusion around SAV subtypes and the diseases they are causing. Nevertheless, it may be appropriate to adopt the name SAVD (with accompanying subtype), at least in a scientific content, to increase the accuracy in denoting SAV-induced diseases.

Conclusions

- **Paper I** comprises the first presentation of the nucleotide sequence from a new subtype of Salmonid Alphavirus (SAV). This new subtype, SAV3, is only found in Norwegian aquaculture of *Salmo salar* and *Oncorhynchus mykiss*.
- Sequence analyses of 20 SAV3 isolates from Norway have shown that SAV3 is a genetic homogenous population, and seem to have an enzootic focus on the west coast of Norway (**Paper II**). The recent disease outbreaks in northern parts of Norway are best explained by transport of SAV3 infected fish from smolt producers located in the enzootic region.
- TaqMan based real-time RT-PCR protocols were developed for detecting RNA from all subtypes of SAV, and can be used to differentiate and quantitate any subtype of salmonid alphavirus within the host (**Paper III**). Using real-time RT-PCR for detection of SAV not only saves time and labour, but also offers increased sensitivity and specificity compared to traditional diagnostic methods.

5 REFERENCES

1. Andersen, L., Bratland, A., Hodneland, K. and Nylund, A., Tissue tropism of Salmonid alphavirus (SAV) in experimentally challenged Atlantic salmon (*Salmo salar* L). Manuscript.
2. Baudin-Laurencin, F., Aldrin, J.F., Messenger, J.L. and Tixerant, G. 1985. Summer pathology in marine cultured rainbow trout. In: A.E. Ellis (Ed), Fish and Shellfish Pathology, Academic Press, San Diego, CA, pp. 211-221.
3. Bell, J.G., McVicar, A.H. and Cowey, C.B., 1987. Pyruvate kinase isozymes in farmed Atlantic salmon (*Salmo salar*): Pyruvate kinase and antioxidant parameters in pancreas disease. *Aquaculture* 66, 33-41.
4. Benmansour, A., Basurco, B., Monnier, A.F., Vende, P., Winton, J.R. and de Kinkelin, P., 1997. Sequence variation of the glycoprotein gene identifies three distinct lineages within field isolates of viral haemorrhagic septicaemia virus, a fish rhabdovirus. *J Gen Virol* 78 (Pt 11), 2837-2846.
5. Boscher, S.K., McLoughlin, M., Le Ven, A., Cabon, J., Baud, M. and Castric, J., 2006. Experimental transmission of sleeping disease in one-year-old rainbow trout, *Oncorhynchus mykiss* (Walbaum), induced by sleeping disease virus. *J Fish Dis* 29, 263-273.
6. Boucher, P. and Baudin Laurencin, F., 1994. Sleeping disease (SD) of salmonids. *Bulletin of the European Association of Fish Pathologists* 14, 179-180.
7. Boucher, P. and Baudin Laurencin, F., 1996a. La Maladie du Sommeil: une pathologie virale proche de la Maladie du Pancreas. "La pisciculture française", revue de la Fédération Française d'Aquaculture N°122, 2-10.
8. Boucher, P. and Baudin Laurencin, F., 1996b. Sleeping disease and pancreas disease: comparative histopathology and aquired cross-protection. *J Fish Dis* 19, 303-310.
9. Boucher, P., Castric, J. and Baudin Laurencin, F., 1994. Observation of virus-like particles in rainbow trout *Oncorhynchus mykiss* infected with sleeping disease virulent material. *Bulletin of the European Association of Fish Pathologists* 14, 215-216.
10. Boucher, P., Raynard, R.S., Houghton, G. and Laurencin, F.B., 1995. Comparative experimental transmission of pancreas disease in Atlantic salmon, rainbow trout and brown trout. *Dis Aquat Organ* 22, 19-24.
11. Branson, E., 2002. Sleeping disease in trout. *Vet Rec* 150, 759-760.
12. Brault, A.C., Powers, A.M., Chavez, C.L., Lopez, R.N., Cachon, M.F., Gutierrez, L.F., Kang, W., Tesh, R.B., Shope, R.E. and Weaver, S.C., 1999. Genetic and antigenic diversity among eastern equine encephalitis viruses from North, Central, and South America. *Am J Trop Med Hyg* 61, 579-586.
13. Brun, E., Poppe, T., Skrudland, A. and Jarp, J., 2003. Cardiomyopathy syndrome in farmed Atlantic salmon *Salmo salar*: occurrence and direct financial losses for Norwegian aquaculture. *Dis Aquat Organ* 56, 241-7.
14. Bruno, D.W., 2004. Changes in prevalence of clinical infectious pancreatic necrosis among fanned Scottish Atlantic salmon, *Salmo salar* L. between 1990 and 2002. *Aquaculture* 235, 13-26.
15. Bustin, S.A., 2000. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. *Journal of Molecular Endocrinology* 25, 169-193.
16. Castric, J., Baudin Laurencin, F., Bremont, M., Jeffroy, J., Le Ven, A. and Bearzotti, M., 1997. Isolation of the virus responsible for sleeping disease in experimentally infected rainbow trout (*Oncorhynchus mykiss*). *Bulletin of the European Association of Fish Pathologists* 17, 27-30.
17. Castric, J., Cabon, J. and Le Ven, A., 2005. Experimental study of vertical transmission of sleeping disease virus (SDV) in rainbow trout (*Oncorhynchus mykiss*). *European Association of Fish Pathologists 12th International Conference of Fish and Shellfish Diseases*, P95.
18. Chamberlain, R.W. 1980. Epidemiology of arthropod-borne togaviruses: The role of arthropods as hosts and vectors and of vertebrate hosts in natural transmission cycles. In: R.W. Schlesinger (Ed), *The Togaviruses: Biology, structure, replication.*, Academic, Orlando, pp. 175-227.
19. Cheng, R.H., Kuhn, R.J., Olson, N.H., Rossmann, M.G., Choi, H.K., Smith, T.J. and Baker, T.S., 1995. Nucleocapsid and glycoprotein organization in an enveloped virus. *Cell* 80, 621-630.
20. Christie, K.E., Fyrand, K., Holtet, L. and Rowley, H.M., 1998. Isolation of pancreas disease virus from farmed Atlantic salmon, *Salmo salar* L., in Norway. *J Fish Dis* 21, 391-394.
21. Crockford, T., Menzies, F.D., McLoughlin, M.F., Wheatley, S.B. and Goodall, E.A., 1999. Aspects of the epizootiology of pancreas disease in farmed Atlantic salmon *Salmo salar* in Ireland. *Dis Aquat Organ* 36, 113-119.
22. de Curtis, I. and Simons, K., 1988. Dissection of Semliki Forest virus glycoprotein delivery from the trans-Golgi network to the cell surface in permeabilized BHK cells. *Proc Natl Acad Sci U S A* 85, 8052-8056.

23. Desvignes, L., Quentel, C., Lamour, F. and Le Ven, A., 2002. Pathogenesis and immune response in Atlantic salmon (*Salmo salar* L.) parr experimentally infected with salmon pancreas disease virus (SPDV). *Fish Shellfish Immun* 12, 77-95.
24. Devold, M., Karlsen, M. and Nylund, A., 2006. Sequence analysis of the fusion protein gene from infectious salmon anaemia virus isolates: evidence of recombination and reassortment. *J Gen Virol* 87, 2031-2040.
25. Domingo, E., Biebricher, C.K., Eigen, M. and Holland, J.J., 2001. Quasispecies and RNA Virus Evolution: Principles and Consequences. Landes Bioscience, Georgetown, TX.
26. Drake, J.W. and Holland, J.J., 1999. Mutation rates among RNA viruses. *Proceedings of the National Academy of Sciences of the United States of America* 96, 13910-13913.
27. Einer-Jensen, K., Ahrens, P., Forsberg, R. and Lorenzen, N., 2004. Evolution of the fish rhabdovirus viral haemorrhagic septicaemia virus. *J Gen Virol* 85, 1167-1179.
28. Ferguson, H.W., Kongtorp, R.T., Taksdal, T., Graham, D. and Falk, K., 2005. An outbreak of disease resembling heart and skeletal muscle inflammation in Scottish farmed salmon, *Salmo salar* L., with observations on myocardial regeneration. *J Fish Dis* 28, 119-123.
29. Ferguson, H.W., Poppe, T. and Speare, D.J., 1990. Cardiomyopathy in farmed Norwegian salmon. *Dis Aquat Organ* 8, 225-231.
30. Ferguson, H.W., Rice, D.A. and Lynas, J.K., 1986a. Clinical pathology of myodegeneration (pancreas disease) in Atlantic salmon (*Salmo salar*). *Vet Rec* 119, 297-299.
31. Ferguson, H.W., Roberts, R.J., Richards, R.H., Collins, R.O. and Rice, D.A., 1986b. Severe degenerative cardiomyopathy associated with pancreas disease in Atlantic salmon, *Salmo Salar* L. *J Fish Dis* 9, 95-98.
32. Frolov, I., Hoffman, T.A., Pragai, B.M., Dryga, S.A., Huang, H.V., Schlesinger, S. and Rice, C.M., 1996. Alphavirus-based expression vectors: Strategies and applications. *Proceedings of the National Academy of Sciences of the United States of America* 93, 11371-11377.
33. Fuller, S.D., 1987. The T=4 envelope of Sindbis virus is organized by interactions with a complementary T=3 capsid. *Cell* 48, 923-934.
34. Fuller, S.D., Berriman, J.A., Butcher, S.J. and Gowen, B.E., 1995. Low pH induces swiveling of the glycoprotein heterodimers in the Semliki Forest virus spike complex. *Cell* 81, 715-725.
35. Gaedigk-Nitschko, K. and Schlesinger, M.J., 1990. The Sindbis virus 6K protein can be detected in virions and is acylated with fatty acids. *Virology* 175, 274-281.
36. Garoff, H. and Cheng, R.H., 2001. The missing link between envelope formation and fusion in alphaviruses. *Trends Microbiol* 9, 408-410.
37. Garoff, H., Hewson, R. and Opstelten, D.J.E., 1998. Virus maturation by budding. *Microbiol Mol Biol R* 62, 1171-1190.
38. Garoff, H., Huylebroeck, D., Robinson, A., Tillman, U. and Liljestrom, P., 1990. The signal sequence of the p62 protein of Semliki Forest virus is involved in initiation but not in completing chain translocation. *J Cell Biol* 111, 867-876.
39. Garoff, H., Simons, K. and Dobberstein, B., 1978. Assembly of the Semliki Forest virus membrane glycoproteins in the membrane of the endoplasmic reticulum in vitro. *J Mol Biol* 124, 587-600.
40. Garoff, H., Sjoberg, M. and Cheng, R.H., 2004. Budding of alphaviruses. *Virus Res* 106, 103-116.
41. Gibbons, D.L., Erk, I., Reilly, B., Navaza, J., Kielian, M., Rey, F.A. and Lepault, J., 2003. Visualization of the target-membrane-inserted fusion protein of Semliki Forest virus by combined electron microscopy and crystallography. *Cell* 114, 573-583.
42. Gibbons, D.L., Vaney, M.C., Roussel, A., Vigouroux, A., Reilly, B., Lepault, J., Kielian, M. and Rey, F.A., 2004. Conformational change and protein-protein interactions of the fusion protein of Semliki Forest virus. *Nature* 427, 320-325.
43. Graham, D., 2005. Longitudinal serological surveys of Atlantic salmon, *Salmo salar* L., using a rapid immunoperoxidase-based neutralization assay for salmonid alphavirus. *J Fish Dis* 28, 373-379.
44. Graham, D., Rowley, H., Todd, D., Jewhurst, V. and Parker, K., 2002. Serological survey for sleeping disease in trout in Northern Ireland. *Vet Rec* 151, 187.
45. Graham, D.A., Jewhurst, V.A., Rowley, H.M., McLoughlin, M.F. and Todd, D., 2003a. A rapid immunoperoxidase-based virus neutralization assay for salmonid alphavirus used for a serological survey in Northern Ireland. *J Fish Dis* 26, 407-413.
46. Graham, D.A., Rowley, H.M., Walker, I.W., Weston, J.H., Branson, E.J. and Todd, D., 2003b. First isolation of sleeping disease virus from rainbow trout, *Oncorhynchus mykiss* (Walbaum), in the United Kingdom. *J Fish Dis* 26, 691-694.
47. Graham, D.A., Taylor, C., Rodgers, D., Weston, J., Khalili, M., Ball, N., Christie, K.E. and Todd, D., 2006. Development and evaluation of a one-step real-time reverse transcription polymerase chain

- reaction assay for the detection of salmonid alphaviruses in serum and tissues. *Dis Aquat Organ* 70, 47-54.
48. Griffin, D.E. 2001. Alphaviruses. In: D.M. Knipe and P.M. Howley (Eds), *Fields Virology*, Vol. 1, Lipincott-Raven Publishers, Philadelphia, pp. 917-962.
 49. Hansen, L.P. and Jacobsen, J.A., 2003. Origin and migration of wild and escaped farmed Atlantic salmon, *Salmo salar* L., in oceanic areas north of the Faroe Islands. *Ices J Mar Sci* 60, 110-119.
 50. Helenius, A., Kartenbeck, J., Simons, K. and Fries, E., 1980. On the entry of Semliki forest virus into BHK-21 cells. *J Cell Biol* 84, 404-420.
 51. Hodneland, K., Bratland, A., Christie, K.E., Endresen, C. and Nylund, A., 2005. New subtype of salmonid alphavirus (SAV), *Togaviridae*, from Atlantic salmon *Salmo salar* and rainbow trout *Oncorhynchus mykiss* in Norway. *Dis Aquat Organ* 66, 113-120.
 52. Hodneland, K. and Endresen, C., 2006. Sensitive and specific detection of Salmonid alphavirus using real-time PCR (TaqMan®). *J Virol Methods* 131, 184-192.
 53. Houghton, G., 1994. Acquired protection in Atlantic salmon, *Salmo salar*, parr and post-smolts against pancreas disease. *Dis Aquat Organ* 18, 109-118.
 54. Houghton, G., 1995. Kinetics of infection of plasma, blood leucocytes and lymphoid tissue from Atlantic salmon, *Salmo salar*, experimentally infected with pancreas disease. *Dis Aquat Organ* 22, 193-198.
 55. Houghton, G. and Ellis, A.E., 1996. Pancreas disease in Atlantic salmon: serum neutralisation and passive immunisation. *Fish Shellfish Immun* 6, 465-472.
 56. Jacobsen, J.A. and Gaard, E., 1997. Open-ocean infestation by salmon lice (*Lepeophtheirus salmonis*): Comparison of wild and escaped farmed Atlantic salmon (*Salmo salar* L.). *Ices J Mar Sci* 54, 1113-1119.
 57. Jacobsen, J.A. and Hansen, L.P., 2001. Feeding habits of wild and escaped farmed Atlantic salmon, *Salmo salar* L., in the Northeast Atlantic. *Ices J Mar Sci* 58, 916-933.
 58. Jarp, J., Gjevre, A.G., Olsen, A.B. and Bruheim, T., 1995. Risk factors for furunculosis, infectious pancreatic necrosis and mortality in post-smolt of Atlantic salmon, *Salmo salar* L. *J Fish Dis* 18, 67-78.
 59. Jewhurst, V.A., Todd, D., Rowley, H.M., Walker, I.W., Weston, J.H., McLoughlin, M.F. and Graham, D.A., 2004. Detection and antigenic characterization of salmonid alphavirus isolates from sera obtained from farmed Atlantic salmon, *Salmo salar* L., and farmed rainbow trout, *Oncorhynchus mykiss* (Walbaum). *J Fish Dis* 27, 143-149.
 60. Karlsten, M., Hodneland, K., Endresen, C. and Nylund, A., 2006. Genetic stability within the Norwegian subtype of salmonid alphavirus (family *Togaviridae*). *Arch Virol* 151, 861-874.
 61. Kent, M.L. and Elston, R.A., 1987. Pancreas disease in net pen reared Atlantic salmon in North America. *Bulletin of the European Association of Fish Pathologists* 7, 29-31.
 62. Kibenge, F.S., Whyte, S.K., Hammell, K.L., Rainnie, D., Kibenge, M.T. and Martin, C.K., 2000. A dual infection of infectious salmon anaemia (ISA) virus and a togavirus-like virus in ISA of Atlantic salmon *Salmo salar* in New Brunswick, Canada. *Dis Aquat Organ* 42, 11-15.
 63. Kielian, M.C., Marsh, M. and Helenius, A., 1986. Kinetics of endosome acidification detected by mutant and wild-type Semliki Forest virus. *Embo J* 5, 3103-3109.
 64. Kongtorp, R.T., Kjerstad, A., Taksdal, T., Guttvik, A. and Falk, K., 2004a. Heart and skeletal muscle inflammation in Atlantic salmon, *Salmo salar* L.: a new infectious disease. *J Fish Dis* 27, 351-358.
 65. Kongtorp, R.T., Taksdal, T. and Lyngoy, A., 2004b. Pathology of heart and skeletal muscle inflammation (HSMI) in farmed Atlantic salmon *Salmo salar*. *Dis Aquat Organ* 59, 217-224.
 66. Koonin, E.V. and Dolja, V.V., 1993. Evolution and taxonomy of positive-strand RNA viruses: implications of comparative analysis of amino acid sequences. *Crit Rev Biochem Mol Biol* 28, 375-430.
 67. Kramer, L.D. and Fallah, H.M., 1999. Genetic variation among isolates of western equine encephalomyelitis virus from California. *Am J Trop Med Hyg* 60, 708-713.
 68. Lanzrein, M., Schlegel, A. and Kempf, C., 1994. Entry and uncoating of enveloped viruses. *Biochem J* 302 (Pt 2), 313-320.
 69. Levinson, R.S., Strauss, J.H. and Strauss, E.G., 1990. Complete sequence of the genomic RNA of O'nyong-nyong virus and its use in the construction of alphavirus phylogenetic trees. *Virology* 175, 110-123.
 70. Liljestrom, P. and Garoff, H., 1991. Internally located cleavable signal sequences direct the formation of Semliki Forest virus membrane proteins from a polyprotein precursor. *J Virol* 65, 147-154.
 71. Liljestrom, P., Lusa, S., Huylebroeck, D. and Garoff, H., 1991. In vitro mutagenesis of a full-length cDNA clone of Semliki Forest virus: the small 6,000-molecular-weight membrane protein modulates virus release. *J Virol* 65, 4107-4113.
 72. Lindsay, M.D., Coelen, R.J. and Mackenzie, J.S., 1993. Genetic heterogeneity among isolates of Ross River virus from different geographical regions. *J Virol* 67, 3576-3585.

73. Linn, M.L., Gardner, J., Warrilow, D., Darnell, G.A., McMahon, C.R., Field, I., Hyatt, A.D., Slade, R.W. and Suhrbier, A., 2001. Arbovirus of marine mammals: a new alphavirus isolated from the elephant seal louse, *Lepidophthirus macrorhini*. *J Virol* 75, 4103-4109.
74. Loewy, A., Smyth, J., von Bonsdorff, C.H., Liljestrom, P. and Schlesinger, M.J., 1995. The 6-kilodalton membrane protein of Semliki Forest virus is involved in the budding process. *J Virol* 69, 469-475.
75. Lopez-Doriga, M.V., Smail, D.A., Smith, R.J., Domenech, A., Castric, J., Smith, P.D. and Ellis, A.E., 2001. Isolation of salmon pancreas disease virus (SPDV) in cell culture and its ability to protect against infection by the 'wild-type' agent. *Fish Shellfish Immun* 11, 505-522.
76. Lusa, S., Garoff, H. and Liljestrom, P., 1991. Fate of the 6K membrane protein of Semliki Forest virus during virus assembly. *Virology* 185, 843-846.
77. Mackay, I.M., Arden, K.E. and Nitsche, A., 2002. Real-time PCR in virology. *Nucleic Acids Research* 30, 1292-1305.
78. Mackenzie, J.S., Poidinger, M., Lindsay, M.D., Hall, R.A. and Sammels, L.M., 1995. Molecular epidemiology and evolution of mosquito-borne flaviviruses and alphaviruses enzootic in Australia. *Virus Genes* 11, 225-237.
79. Manrubia, S.C., Escarmis, C., Domingo, E. and Lazaro, E., 2005. High mutation rates, bottlenecks, and robustness of RNA viral quasispecies. *Gene* 347, 273-282.
80. McCoy, M.A., McLoughlin, M.F., Rice, D.A. and Kennedy, D.G., 1994. Pancreas disease in Atlantic salmon (*Salmo salar*) and vitamin E supplementation. *Comparative Biochemistry and Physiology a-Physiology* 109, 905-912.
81. McLoughlin, M.F., 1997. The differential diagnosis of the major pancreatic disorders of salmonids, a diagnostic challenge. *Bulletin of the European Association of Fish Pathologists* 17, 205-208.
82. McLoughlin, M.F., Nelson, R.N., McCormick, J.I., Rowley, H.M. and Bryson, D.B., 2002. Clinical and histopathological features of naturally occurring pancreas disease in farmed Atlantic salmon, *Salmo salar* L. *J Fish Dis* 25, 33-43.
83. McLoughlin, M.F., Nelson, R.T., McCormick, J.I. and Rowley, H., 1995. Pathology of experimental pancreas disease in freshwater Atlantic salmon (*Salmo salar*) parr. *Journal of Aquatic Animal Health* 7, 104-110.
84. McLoughlin, M.F., Nelson, R.T., Rowley, H.M., Cox, D.I. and Grant, A.N., 1996. Experimental pancreas disease in Atlantic salmon *Salmo salar* post-smolts induced by salmon pancreas disease virus (SPDV). *Dis Aquat Organ* 26, 117-124.
85. McLoughlin, M.F., Rowley, H.M. and Doherty, C.E., 1998. A serological survey of salmon pancreas disease virus (SPDV) antibodies in farmed Atlantic salmon, *Salmo salar* L. *J Fish Dis* 21, 305-307.
86. McVicar, A.H., 1986. A spreading threat to salmon. *Fish Farmer* 9, 18-19.
87. McVicar, A.H., 1987. Pancreas disease of farmed Atlantic salmon, *Salmo salar* in Scotland: epidemiology and early pathology. *Aquaculture* 67, 71-78.
88. McVicar, A.H., 1990. Infection as primary cause of pancreas disease in farmed Atlantic salmon. *Bulletin of the European Association of Fish Pathologists* 10, 84-87.
89. Melton, J.V., Ewart, G.D., Weir, R.C., Board, P.G., Lee, E. and Gage, P.W., 2002. Alphavirus 6K proteins form ion channels. *J Biol Chem* 277, 46923-46931.
90. Moriette, C., LeBerre, M., Boscher, S.K., Castric, J. and Brémont, M., 2005. Characterization and mapping of monoclonal antibodies against the *Sleeping disease virus*, an aquatic alphavirus. *The Journal of general virology* 86, 3119-3127.
91. Moriette, C., LeBerre, M., Lamoureux, A., Lai, T.L. and Bremont, M., 2006. Recovery of a recombinant salmonid alphavirus fully attenuated and protective for rainbow trout. *J Virol* 80, 4088-4098.
92. Mrkic, B., Tetaz, T. and Kempf, C., 1997. Cleavage of incoming Semliki Forest virus capsid protein within the endocytotic pathway: a feature common to both invertebrate and mammalian cells. *Arch Virol* 142, 1895-1902.
93. Munro, A.L.S., Ellis, A.E., McVicar, A.H., Mclay, H.A. and Needham, E.A., 1984. An exocrine pancreas disease of farmed Atlantic salmon in Scotland. *Helgolander Meeresun* 37, 571-586.
94. Murphy, T.M., Rodger, H.D., Drinan, E.M., Gannon, F., Kruse, P. and Korting, W., 1992. The sequential pathology of pancreas disease in Atlantic salmon farms in Ireland. *J Fish Dis* 15, 401-408.
95. Nelson, R.T., McLoughlin, M.F., Rowley, H.M., Platten, M.A. and McCormick, J.I., 1995. Isolation of a toga-like virus from farmed Atlantic salmon *Salmo salar* with pancreas disease. *Dis Aquat Organ* 22, 25-32.
96. Nylund, A., Devold, M., Plarre, H., Isdal, E. and Aarseth, M., 2003a. Emergence and maintenance of infectious salmon anaemia virus (ISAV) in Europe: a new hypothesis. *Dis Aquat Organ* 56, 11-24.

96. Nylund, A., Plarre, H., Hodneland, K., Devold, M., Aspehaug, V., Aarseth, M., Koren, C. and Watanabe, K., 2003b. Haemorrhagic smolt syndrome (HSS) in Norway: pathology and associated virus-like particles. *Diseases of Aquatic Organisms* 54, 15-27.
97. Nylund, A., Plarre, H., Karlsen, M., Fridell, F., Ottem, K.F., Bratland, A. and Sæter, P.A., 2006. Transmission of infectious salmon anaemia virus (ISAV) in farmed populations of Atlantic salmon (*Salmo salar*). *Archives of Virology* in press.
98. Oberste, M.S., Schmura, S.M., Weaver, S.C. and Smith, J.F., 1999. Geographic distribution of Venezuelan equine encephalitis virus subtype IE genotypes in Central America and Mexico. *Am J Trop Med Hyg* 60, 630-634.
99. Olsen, A.B. and Wangel, C., 1997. An outbreak of pancreas disease (PD) in rainbow trout (*Oncorhynchus mykiss*). *European Association of Fish Pathologists 8th International Conference of Fish and Shellfish Diseases*, P-062.
100. Olsvik, P.A., Lie, K.K., Jordal, A.E., Nilsen, T.O. and Hordvik, I., 2005. Evaluation of potential reference genes in real-time RT-PCR studies of Atlantic salmon. *BMC Mol Biol* 6, 21.
101. Paredes, A.M., Brown, D.T., Rothnagel, R., Chiu, W., Schoepp, R.J., Johnston, R.E. and Prasad, B.V., 1993. Three-dimensional structure of a membrane-containing virus. *Proc Natl Acad Sci U S A* 90, 9095-9099.
102. Pfaffl, M.W., 2001. A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res* 29, e45.
103. Poppe, T., Rimstad, E. and Hyllseth, B., 1989. Pancreas disease in Atlantic salmon (*Salmo salar*) post-smolts infected with infectious pancreatic necrosis (IPNV). *Bulletin of the European Association of Fish Pathologists* 9, 83-85.
104. Powers, A.M., Brault, A.C., Shirako, Y., Strauss, E.G., Kang, W.L., Strauss, J.H. and Weaver, S.C., 2001. Evolutionary relationships and systematics of the alphaviruses. *J Virol* 75, 10118-10131.
105. Pringle, G.M., Houlihan, D.F., Callanan, K.R., Mitchell, A.I., Raynard, R.S. and Houghton, G.H., 1992. Digestive enzyme levels and histopathology of pancreas disease in farmed Atlantic salmon (*Salmo salar*). *Comp Biochem Phys A* 102, 759-768.
106. Raynard, R.S. and Houghton, G., 1993. Development towards an experimental protocol for the transmission of pancreas disease of Atlantic salmon *Salmo salar*. *Dis Aquat Organ* 15, 123-128.
107. Raynard, R.S., Mevicar, A.H., Bell, J.G., Youngson, A., Knox, D. and Fraser, C.O., 1991. Nutritional aspects of pancreas disease of Atlantic salmon: the effects of dietary vitamin E and polyunsaturated fatty acids. *Comp Biochem Phys A* 98, 125-131.
108. Rice, C.M., Levis, R., Strauss, J.H. and Huang, H.V., 1987. Production of infectious RNA transcripts from Sindbis virus cDNA clones: mapping of lethal mutations, rescue of a temperature-sensitive marker, and in vitro mutagenesis to generate defined mutants. *J Virol* 61, 3809-3819.
109. Roberts, R.J. 1989. The pathophysiology and systematic pathology of teleosts. In: R.J. Roberts (Ed), *Fish Pathology*, Ballière Tindall, London, pp. 56-63.
110. Rodger, H.D., 1991. Summer lesion syndrome in salmon - a retrospective study. *Vet Rec* 129, 237-239.
111. Rodger, H.D., Murphy, K., Drinan, E.M. and Kennedy, G., 1995. Apparent lack of response of salmon affected by pancreas disease to pancreatic enzyme replacement therapy. *Vet Rec* 136, 489-491.
112. Rodger, H.D., Turnbull, T. and Richards, R.H., 1994. Myopathy and pancreas disease in salmon: a retrospective study in Scotland. *Vet Rec* 135, 234-235.
113. Rowley, H.M., Doherty, C.E., McLoughlin, M.F. and Welsh, M.D., 1998. Isolation of salmon pancreas disease virus (SPDV) from farmed Atlantic salmon, *Salmo salar* L., in Scotland. *J Fish Dis* 21, 469-471.
114. Sanz, M.A. and Carrasco, L., 2001. Sindbis virus variant with a deletion in the 6K gene shows defects in glycoprotein processing and trafficking: lack of complementation by a wild-type 6K gene in trans. *J Virol* 75, 7778-7784.
115. Sanz, M.A., Madan, V., Carrasco, L. and Nieva, J.L., 2003. Interfacial domains in Sindbis virus 6K protein. Detection and functional characterization. *J Biol Chem* 278, 2051-2057.
116. Schlesinger, S. and Dubensky, T.W., 1999. Alphavirus vectors for gene expression and vaccines. *Curr Opin Biotechnol* 10, 434-439.
117. Schlesinger, S. and Schlesinger, M.J. 2001. *Togaviridae: The viruses and their replication*. In: D.M. Knipe and P.M. Howley (Eds), *Fields Virology*, Vol. 1, Lipincott-Raven Publishers, Philadelphia, pp. 895-916.
118. Smail, D.A., Bain, N., Bruno, D.W., King, J.A., Thompson, F., Pendrey, D.J., Morrice, S. and Cunningham, C.O., 2006. Infectious pancreatic necrosis virus in Atlantic salmon, *Salmo salar* L., post-smolts in the Shetland Isles, Scotland: virus identification, histopathology, immunohistochemistry and genetic comparison with Scottish mainland isolates. *J Fish Dis* 29, 31-41.

119. Snow, M., Bain, N., Black, J., Taupin, V., Cunningham, C.O., King, J.A., Skall, H.F. and Raynard, R.S., 2004. Genetic population structure of marine viral haemorrhagic septicaemia virus (VHSV). *Dis Aquat Organ* 61, 11-21.
120. Sommerset, I., Krossoy, B., Biering, E. and Frost, P., 2005. Vaccines for fish in aquaculture. *Expert Rev Vaccines* 4, 89-101.
121. Steinhauer, D.A., Domingo, E. and Holland, J.J., 1992. Lack of evidence for proofreading mechanisms associated with an RNA virus polymerase. *Gene* 122, 281-288.
122. Steinhauer, D.A. and Holland, J.J., 1987. Rapid evolution of RNA viruses. *Annu Rev Microbiol* 41, 409-433.
123. Strauss, J.H. and Strauss, E.G., 1994. The alphaviruses: gene expression, replication, and evolution. *Microbiol Rev* 58, 491-562.
124. Takkinen, K., 1986. Complete nucleotide sequence of the nonstructural protein genes of Semliki Forest virus. *Nucleic Acids Res* 14, 5667-5682.
125. Taksdal, T., McLoughlin, M., KE, C., Olsen, A.B. and Todd, D., 2003. Pancreas disease (PD): Immunohistochemical detection of virus antigen in acute pancreatic lesions. 11th International Conference of the European Association of Fish Pathologists, P-07.
126. Taksdal, T., Ramstad, A., Stangeland, K. and Dannevig, B.H., 1998. Induction of infectious pancreatic necrosis (IPN) in covertly infected Atlantic salmon, *Salmo salar* L., post smolts by stress exposure, by injection of IPN virus (IPNV) and by cohabitation. *J Fish Dis* 21, 193-204.
127. Thiery, R., de Boisseson, C., Jeffroy, J., Castric, J., de Kinkelin, P. and Benmansour, A., 2002. Phylogenetic analysis of viral haemorrhagic septicaemia virus (VHSV) isolates from France (1971-1999). *Dis Aquat Organ* 52, 29-37.
128. Thorud, K. 1991. Infectious salmon anaemia: transmission trials, haematological, clinical, chemical and morphological investigations., Norwegian College of Veterinary Medicine, Oslo, Norway, Vol. 9, pp. 83-85.
129. Tjensvoll, K., Glover, K.A. and Nylund, A., 2006. Sequence variation in four mitochondrial genes of the salmon louse *Lepeophtheirus salmonis*. *Dis Aquat Organ* 68, 251-259.
130. Todd, D., Jewhurst, V.A., Welsh, M.D., Borghmans, B.J., Weston, J.H., Rowley, H.M., Mackie, D.P. and McLoughlin, M.F., 2001. Production and characterisation of monoclonal antibodies to salmon pancreas disease virus. *Dis Aquat Organ* 46, 101-108.
131. Villoing, S., Bearzotti, M., Chilmoneczyk, S., Castric, J. and Bremont, M., 2000a. Rainbow trout sleeping disease virus is an atypical alphavirus. *J Virol* 74, 173-183.
132. Villoing, S., Castric, J., Jeffroy, J., Le Ven, A., Thiery, R. and Bremont, M., 2000b. An RT-PCR-based method for the diagnosis of the sleeping disease virus in experimentally and naturally infected salmonids. *Dis Aquat Organ* 40, 19-27.
133. Vogel, R.H., Provencher, S.W., von Bonsdorff, C.H., Adrian, M. and Dubochet, J., 1986. Envelope structure of Semliki Forest virus reconstructed from cryo-electron micrographs. *Nature* 320, 533-535.
134. Wahlberg, J.M. and Garoff, H., 1992. Membrane fusion process of Semliki Forest virus. I: Low pH-induced rearrangement in spike protein quaternary structure precedes virus penetration into cells. *J Cell Biol* 116, 339-348.
135. Watanabe, K., Hovland, T., Nylund, A. and Endresen, C., 1993. Påvisning og lokalisering av ILA viruset hos laks. *Norsk Fiskeoppdrett* 8, 64-65.
136. Watanabe, K., Karlsen, M., Devold, M., Isdal, E., Litlabø, A. and Nylund, A., 2006. Virus-like particles associated with heart and skeletal muscle inflammation (HSMI). *Dis Aquat Organ* 70, 183-192.
137. Weaver, S.C. 1995. Molecular basis of virus evolution. In: A. Gibbs, C. Calisher and F. García-Arenal (Eds), *Fields Virology*, Cambridge University Press, Cambridge, United Kingdom., pp. 501-530.
138. Weaver, S.C., Ferro, C., Barrera, R., Boshell, J. and Navarro, J.C., 2004. Venezuelan equine encephalitis. *Annu Rev Entomol* 49, 141-174.
139. Weaver, S.C., Kang, W., Shirako, Y., Rumenapf, T., Strauss, E.G. and Strauss, J.H., 1997. Recombinational history and molecular evolution of western equine encephalomyelitis complex alphaviruses. *J Virol* 71, 613-623.
140. Weaver, S.C., Rico-Hesse, R. and Scott, T.W., 1992. Genetic diversity and slow rates of evolution in New World alphaviruses. *Curr Top Microbiol Immunol* 176, 99-117.
141. Welsh, M., Weston, J., Borghmans, B.J., Mackie, D., Rowley, H., Nelson, R., McLoughlin, M. and Todd, D., 2000. Biochemical characterization of salmon pancreas disease virus. *J Gen Virol* 81, 813-820.
142. Weston, J., Villoing, S., Bremont, M., Castric, J., Pfeffer, M., Jewhurst, V., McLoughlin, M., Rodseth, O., Christie, K.E., Koumans, J. and Todd, D., 2002. Comparison of two aquatic alphaviruses, salmon pancreas disease virus and sleeping disease virus, by using genome sequence analysis, monoclonal reactivity, and cross-infection. *J Virol* 76, 6155-6163.

143. Weston, J.H., Graham, D.A., Branson, E., Rowley, H.M., Walker, I.W., Jewhurst, V.A., Jewhurst, H.L. and Todd, D., 2005. Nucleotide sequence variation in salmonid alphaviruses from outbreaks of salmon pancreas disease and sleeping disease. *Dis Aquat Organ* 66, 105-111.
144. Weston, J.H., Welsh, M.D., McLoughlin, M.F. and Todd, D., 1999. Salmon pancreas disease virus, an alphavirus infecting farmed Atlantic salmon, *Salmo salar* L. *Virology* 256, 188-195.
145. Wilke, C.O., 2005. Quasispecies theory in the context of population genetics. *BMC Evol Biol* 5, 44.
146. Yao, J.S., Strauss, E.G. and Strauss, J.H., 1996. Interactions between PE2, E1, and 6K required for assembly of alphaviruses studied with chimeric viruses. *J Virol* 70, 7910-7920.
147. Zhang, C.X. and Suzuki, S., 2004. Aquabirnaviruses isolated from marine organisms form a distinct genogroup from other aquabirnaviruses. *J Fish Dis* 27, 633-643.
148. Østvik, A. and Kjerstad, A., 2002. En kartlegging av utbredelse, tap og økonomiske konsekvenser av kardiomyopatisyndrom (CMS) og andre hjertelidelser på Atlantisk laks. *Fiskehelse* 2, 15-18.